pre-IPO PHARMA

TAG: Oncology

Sep 28, 2023

PIC Therapeutics Expands its Team with the Addition of Translational Biology Oncology Leader, Richard Gedrich, PhD as Chief Development Officer


Sep 28, 2023

First Patient Dosed in Phase 1b Clinical Trial of Synthekine’s α/β Biased IL-2, STK-012, for Treatment of Solid Tumors


Sep 27, 2023

HotSpot Therapeutics to Present Preclinical Data from CBL-B Program at 2023 Society for Immunotherapy of Cancer Annual Meeting


Sep 27, 2023

Tallac Therapeutics Announces Two Abstracts Accepted for Presentation at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting


Sep 27, 2023

Venatorx Pharmaceuticals to Present at IDWeek 2023



Sep 26, 2023

Cantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer


Sep 21, 2023

AffyImmune Therapeutics Named 2023 Scrip Award Finalist for Best Oncology RandD Advance


Sep 18, 2023

KayoThera, Inc. Nominates First-in-Class, Oral Inhibitor of the Retinoid Pathway in Genetically Defined Oncology Indications as a Development Candidate


Sep 18, 2023

FDA Notifies Osmol Therapeutics that the First-in-Human Phase 1 Clinical Trial of OSM-0205 for the Prevention of Chemotherapy-induced Peripheral Neuropathy (CIPN) May Proceed


Sep 18, 2023

LinKinVax and Gustave Roussy Announced First Patient Dosed in Phase I/IIa Clinical Study on HPV.DCVax in HPV-positive Oropharyngeal Cancer



Sep 15, 2023

Therapeutic Solutions International Subsidiary Discloses Potential Solution to Immunotherapy Resistance in Cancer by “Healing Tumor” Before Killing It


Sep 13, 2023

Calidi Biotherapeutics Debuts as a Publicly Traded Company Focused on Arming the Immune System to Fight Cancer with a New Generation of Targeted Immunotherapies


Sep 11, 2023

AVM Biotechnology Selected by the National Cancer Institute to Present at Bio Investor Forum 2023


Sep 7, 2023

Phanes Therapeutics Announces First Patient Dosed in Phase 1 Study of PT217 for Small Cell Lung Cancer and Other Neuroendocrine Cancers Expressing DLL3


Sep 6, 2023

Nimbus Therapeutics Secures $210M Private Financing to Advance Next Wave of Tech-Enabled Small Molecule Medicines



Sep 5, 2023

CG Oncology Announces Key Executive Appointments in Commercialization, Medical and Manufacturing Operations


Sep 5, 2023

Phanes Therapeutics Announces the Establishment of Oncology Clinical Advisory Board


Aug 22, 2023

Geneos Therapeutics Announces Eight of 34 Patients to Achieve Complete Response, Complete Molecular Response, or, Secondary Resectability in Ongoing Clinical Trial of Personalized Therapeutic Cancer Vaccination in Second Line Advanced Liver Cancer


Aug 10, 2023

Cantex Pharmaceuticals Announces Article Published in npj Breast Cancer Highlighting Potential Role of RAGE Inhibition to Prevent Metastasis in Triple-Negative Breast Cancer


Aug 10, 2023

Rakuten Medical and Hikma Sign Exclusive Licensing Agreement for Alluminox™ Platform Cancer Treatment in the Middle East and North Africa



Aug 9, 2023

AVM Biotechnology Announces that the National Cancer Institute has selected AVM Biotechnology as a Showcase Company for their 2023-2024 Small Business Innovation Research (SBIR) Investor Initiatives


Aug 8, 2023

Imvax Announces Publication in Journal for ImmunoTherapy of Cancer Showing IGV-001 Can Induce Clinically Relevant Anti-Cancer Immune Responses in Glioblastoma via Immunogenic Cell Death


Aug 2, 2023

CG Oncology Announces $105 Million Oversubscribed Crossover Financing to Advance Clinical-Stage Bladder Cancer Pipeline


Aug 1, 2023

AVM Biotechnology Announces Twenty-Eight (28) Solid Tumor and Blood Cancer Patients have been Treated with Immunomodulatory AVM0703 through Expanded Access/Compassionate Use Programs


Jul 27, 2023

Cullgen Announces First-In-Human Dose in Phase I/II Trial of CG001419, a First-in-Class TRK Protein Degrader for Treatment of Cancer Patients



Jul 25, 2023

Epsilogen Announces Successful Completion of First Ever Clinical Trial of an IgE Antibody; Phase I Data for MOv18 IgE Demonstrates Potential of IgE Therapy in Cancer


Jul 24, 2023

CG Oncology Completes Patient Enrollment in BOND-003 Phase 3 Monotherapy Study with Cretostimogene Grenadenorepvec in BCG-Unresponsive High-Risk NMIBC


Jul 20, 2023

Elucida Oncology Announces First Patient Dosed with ELU001 in Expansion Cohort of its Phase 1/2 Clinical Trial


Jul 19, 2023

KayoThera, Inc. Strengthens Financial Position with $5.2 Million in Grant and Expanded Series A Funding, Bringing Total Financial Support to $14 Million


Jul 18, 2023

Therapeutic Solutions International Subsidiary Res Nova Bio Inc Discovers New Mechanism of Action for Breast Cancer Immunotherapy Adjuvant FloraStilbene™



Jul 13, 2023

KSQ Therapeutics Enters Worldwide License Agreement with Roche for KSQ-4279, a Clinical-Stage USP1 Inhibitor for Cancer


Jul 13, 2023

Nitrase Therapeutics Announces Publication in the Journal of Biological Chemistry on the Role of Tyrosine Nitration in Cell Signaling and Cancer Biology


Jul 12, 2023

BPGbio Announces Partnership with Grupo Terralpe to Offer Groundbreaking AI-Discovered Prostate Cancer Diagnostic Test in Mexico


Jul 10, 2023

First Safety and Efficacy Data of Rakuten Medical's Alluminox Treatment using ASP-1929 in Combination with anti-PD-1 for Recurrent and/or Metastatic Head and Neck Cancer Presented at AHNS 2023


Jul 10, 2023

CancerVAX CEO Ryan Davies Discusses Biotech Entrepreneurship with Pyxis Oncology CEO Dr. Lara Sullivan



Jul 6, 2023

Shorla Oncology Announces Licensing Agreement and Strategic Partnership for Rights to Market Chemotherapy Drug, PIP-101, in the United States


Jun 30, 2023

Transcenta Presented PFS Data by CLDN18.2 Expression Level from Phase I/II Study of Osemitamab (TST001) plus CAPOX as the First-Line Treatment of Advanced G/GEJ Cancer at ESMO GI Annual Congress 2023 USA - English APAC - English


Jun 30, 2023

Toragen, Inc. Announces Initiation of Phase 1 Trial of TGN-S11 in Patients with Human Papillomavirus-Induced Cancer


Jun 29, 2023

Bexion Pharmaceuticals, Inc. to Present at the ESMO World Congress on Gastrointestinal Cancer 2023


Jun 29, 2023

Liver Cancer Market to Proliferate Positively, Assesses DelveInsight | Key Companies Active in the Domain - SOTIO, GlaxoSmithKline, Pfizer, Merck, Takeda, Genentech, Boehringer Ingelheim, DNAtrix, Celldex



Jun 27, 2023

CancerVAX Reports Significant Progress on Universal Cancer Vaccine Development at UCLA


Jun 26, 2023

Sermonix Pharmaceuticals Announces Article Comparing ‘Traditional’ to ‘Just-in-Time’ Trial Enrollment Models Is Published in JCO Clinical Cancer Informatics


Jun 23, 2023

Calidi Biotherapeutics Announces Commitment of $25 Million in Series B Funding to Advance Stem Cell-Based Platforms for the Delivery and Potentiation of Oncolytic Viruses to Treat Cancer


Jun 15, 2023

CANTEX PHARMACEUTICALS TO PRESENT AT THE MEDINVEST ONCOLOGY INVESTOR CONFERENCE IN BOSTON


Jun 15, 2023

AKTIS ONCOLOGY EXPANDS SCIENTIFIC ADVISORY BOARD TO ADVANCE PIPELINE OF TARGETED ALPHA RADIOPHARMACEUTICALS



Jun 15, 2023

Flamingo Therapeutics Receives €1.7M Grant Award from VLAIO to Advance RNA-Targeting Oncology Portfolio Danmark - English USA - English Danmark - Dansk


Jun 13, 2023

ITM Opens World's Largest Lutetium-177 Production Facility for Targeted Radionuclide Therapies Against Cancer


Jun 12, 2023

CancerVAX Reports Positive Progress on Kids Cancer Immunotherapy Treatment


Jun 6, 2023

AKTIS ONCOLOGY TO PARTICIPATE IN JEFFERIES HEALTHCARE CONFERENCE


Jun 6, 2023

Bold Therapeutics Presents Positive Interim Phase 2 Results for BOLD-100 in Advanced Gastric and Biliary Tract Cancer at ASCO 2023



Jun 6, 2023

Eureka Therapeutics Awarded $10.6 Million CIRM Grant to Support Clinical Trial of ARTEMIS T-Cell Therapy in Pediatric Liver Cancer


Jun 6, 2023

CancerVAX CEO Ryan Davies and Raymond Vennare Discuss the Cancer Fighting Role of Universities


Jun 5, 2023

Domain Therapeutics announces nomination of first-in-class PAR2 NAM candidate, DT-9045, to unlock new cancer treatment possibilities


Jun 5, 2023

Sermonix Pharmaceuticals Shares ASCO Poster Presentation on Longer Patient Follow-up Results for ELAINE-2 Study in ESR1-mutated Metastatic Breast Cancer


Jun 5, 2023

NKGen Biotech Announces SNK01 Preclinical and Phase I/IIa Clinical Data Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting



Jun 5, 2023

Transcenta Presents Updated Data of Osemitamab (TST001) in Combination with CAPOX as a First-Line Treatment of G/GEJ Cancer at 2023 ASCO Annual Meeting USA - English APAC - English


Jun 5, 2023

Morphogenesis, Inc. and CohBar, Inc. Announce Positive Results from Phase 1b Trial of IFx-Hu2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)


Jun 3, 2023

Elicio Therapeutics Announces Positive Interim Data from the Phase 1 Study of an Investigational Therapeutic Cancer Immunotherapy, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancer at the ASCO Annual Meeting


Jun 2, 2023

Affini-T Therapeutics Appoints Industry Veteran Thaminda Ramanayake, M.S., MBA, as Chief Business Officer


Jun 1, 2023

Bayer to acquire exclusive license from Cedilla Therapeutics on selective inhibitors in pre-clinical precision oncology



Jun 1, 2023

Bold Therapeutics to Present Positive Interim Gastric and Biliary Tract Cancer Results at ASCO 2023 Annual Meeting


Jun 1, 2023

Shasqi Announces Research Collaboration to Transform Targeted Cancer Treatment


May 31, 2023

Cartography Biosciences Expands Scientific Advisory Board with Leading Antibody and Bi-specific Experts


May 30, 2023

Morphogenesis, Inc. and CohBar, Inc. Announce Acceptance of Abstract for Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting


May 30, 2023

AUM Biosciences Doses First Patient in Phase 2 Clinical Trial of AUM001 in Metastatic Colorectal Cancer



May 25, 2023

Affini-T Therapeutics to Present AFNT-211 T Cell Product Attributes Targeting KRAS G12V at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting


May 25, 2023

AffyImmune Therapeutics Announces Positive Safety and Early Efficacy Results from Phase 1 Study of AIC100 CAR T Cells in Anaplastic and Advanced Thyroid Cancers at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting


May 25, 2023

Cartography Biosciences Appoints Industry Veteran as Chief Administrative and Legal Officer


May 23, 2023

CohBar, Inc. and Morphogenesis, Inc. Enter into Definitive Merger Agreement to Advance an Innovative Late-stage Clinical Immuno-oncology Pipeline of Therapies to Overcome Resistance to Cancer Immunotherapy


May 22, 2023

Rakuten Medical to Start a Global Phase 3 Trial of Alluminox™ Treatment using ASP-1929 for Recurrent Head and Neck Cancer in India



May 22, 2023

Therapeutic Solutions International Spin-Off Res Nova Bio Leverages FDA Cleared Tumor Blood Vessel Targeting Technology to Intravenously Deliver Cancer Killing Viruses


May 22, 2023

Outpace Bio Expands Seattle Presence with Cell Therapy Research Hub and Collaborations with Leading Experts in Protein Design and Cancer Immunotherapy


May 22, 2023

BPGbio Announces New Partnership with DoD Focused on AI-Guided Breast Cancer Diagnostics


May 17, 2023

Indapta Therapeutics Announces U.S. FDA Clearance of IND for IDP-023, an Allogeneic Natural Killer (NK) Cell Therapy for Cancer


May 16, 2023

Boundless Bio Announces $100 Million Oversubscribed Series C Financing co-led by Leaps by Bayer and RA Capital Management to Advance the First ecDNA-Directed Therapies (ecDTx) for Patients with Oncogene Amplified Cancer



May 16, 2023

Olatec Therapeutics Announces the Completion of First Dose Cohort in an Innovative Trial Investigating Olatec’s NLRP3 Inhibitor Dapansutrile and Merck’s Keytruda in Patients with Advanced Refractory Melanoma at Duke Cancer Institute


May 16, 2023

ArsenalBio Announces Presentations Highlighting Preclinical Data on AB-1015 and AB-2100 at ASGCT Annual Meeting


May 15, 2023

Therapeutic Solutions International Spin-Off Res Nova Bio Partners with Cure Stat Rx to Manufacture First in Class Breast Cancer Immunotherapy Product FloraStilbene™


May 12, 2023

AKTIS ONCOLOGY TO PARTICIPATE IN 2023 GUGGENHEIM HEALTHCARE TALKS: RADIOPHARMACEUTICALS DAY


May 10, 2023

Wugen Appoints Industry Leader Mark Alles as Chair of the Board of Directors



May 9, 2023

Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-355 in Patients with Solid Tumors Harboring Oncogene Amplification


May 4, 2023

SNIPR Biome's data on first clinical drug candidate to prevent infections in hematological cancer patients published in Nature Biotechnology USA - English USA - English


May 2, 2023

Scorpion Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of STX-478, Its Mutant-Selective PI3Kα Inhibitor for the Treatment of Breast Cancer and Other Solid Tumors


May 1, 2023

CG Oncology Announces New Phase 2 Data with Cretostimogene Grenadenorepvec (CG0070) in Combination with KEYTRUDA (pembrolizumab) in BCG-Unresponsive NMIBC


May 1, 2023

Elicio Therapeutics to Present Interim Data from the Ongoing Phase 1 Study of Investigational Therapeutic Cancer Vaccine, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancer at ASCO



Apr 27, 2023

OncoNano Medicine Announces Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023


Apr 27, 2023

ITM Enters Cooperation Agreement with Paul Scherrer Institute (PSI) for Co-Development and Upscaled Manufacturing of Terbium-161 for Theranostic Application in Cancer


Apr 26, 2023

Tevogen Bio CSO to Discuss Investigational T Cell Therapy at NOLA Conference Focused on Long COVID and COVID-Related Cancer Risk, Alongside Leading Oncology Experts


Apr 26, 2023

Bicara Therapeutics Announces Oral Presentation of Head and Neck Cancer Dose Expansion Data from Phase 1/1b Study of BCA101 at Upcoming 2023 ASCO Annual Meeting


Apr 26, 2023

Avenge Bio Announces Successful Completion of First Dose Level Cohort in Phase 1/2 Clinical Trial of AVB-001 for the Treatment of Ovarian Cancer



Apr 26, 2023

FORE Biotherapeutics Announces Two Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting


Apr 25, 2023

Turn Biotechnologies to Discuss Promise of Epigenetic Reprogramming in CAR-T Cell Therapy at World Oncology Cell Therapy Congress


Apr 24, 2023

Dyve Biosciences Presents Preclinical Data from Lead Oncology Drug Candidate, DYV800, at the American Association for Cancer Research 2023 Annual Meeting


Apr 20, 2023

Edison Oncology Announces Presentation of Two Scientific Posters at AACR Annual Meeting


Apr 20, 2023

Elucida Oncology Announces Positive Early Phase 1 Safety Data Along with Preclinical Data for the Treatment of Brain Metastases for ELU001, an Anti-Folate Receptor Alpha C’Dot Drug Conjugate



Apr 19, 2023

Bicara Therapeutics Announces Publication in Cancer Research Describing Design and Characterization of Lead Bifunctional Antibody Program, BCA101


Apr 19, 2023

Circle Pharma’s first-in-class orally bioavailable macrocyclic cyclin A/B inhibitors highlighted in poster presentations at American Association for Cancer Research Annual Meeting


Apr 19, 2023

Wugen Presents New Preclinical Data Reinforcing Anti-Tumor Functionality of WU-NK-101 at the American Association for Cancer Research (AACR) Annual Meeting 2023


Apr 18, 2023

Bold Therapeutics Presents Jaw-Dropping Interim Phase 2 Clinical Data for BOLD-100 in the Treatment of Advanced Colorectal Cancer at AACR 2023


Apr 18, 2023

EvolveImmune Therapeutics Reports First Results from CRISPR-Cas9 T Cell Exhaustion Screening Platform at American Association for Cancer Research (AACR) Annual Meeting 2023



Apr 18, 2023

Grey Wolf Therapeutics Reports Promising Preclinical Data from Research Collaboration with Immunocore in Oral Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023


Apr 18, 2023

Nouscom Presents New Positive Translational Phase 1b Data of NOUS-PEV, a Personalized Neoantigen Cancer Immunotherapy, in a Late-Breaking Abstract at AACR 2023


Apr 18, 2023

Nitrase Therapeutics Presents Preclinical Data on the Role of Enzymatic Nitration in Oncology at the American Association for Cancer Research Annual Meeting


Apr 17, 2023

Boundless Bio Presents Data on the Novel Discovery of CHK1 as an Extrachromosomal DNA (ecDNA) Essential Target in Oncogene Amplified Cancers at the American Association for Cancer Research Annual Meeting 2023


Apr 17, 2023

Dragonfly Therapeutics Announces the Publication of Preclinical Data Supporting DF6002, its Extended Half-life IL-12 Cytokine, as A Promising Treatment for Cancer USA - English USA - English USA - Deutsch USA - español USA - Français



Apr 17, 2023

Myeloid Therapeutics Presents Late-Breaking Data on Multiple Platforms at the American Association for Cancer Research (AACR) 2023 Annual Meeting


Apr 17, 2023

PIC Therapeutics Presents Pre-Clinical Data Update on eIF4E Regulators at AACR Annual Meeting 2023


Apr 16, 2023

Accent Therapeutics Presents Data Supporting DHX9 Inhibition as a Novel Therapeutic Modality at American Association for Cancer Research (AACR) Annual Meeting 2023


Apr 16, 2023

Researchers Report Clinical Proof-of-Concept Data for Vivace Therapeutics' VT3989, a First for a Cancer Drug Targeting the Hippo Pathway, in Oral Presentation at AACR 2023


Apr 15, 2023

Bexion Pharmaceuticals, Inc. to Present at the 2023 American Association for Cancer Research (AACR) Annual Meeting and the International Ceramide Conference (ICC)



Apr 14, 2023

Flamingo Therapeutics Announces Poster Presentation on FTX-001 at the 2023 American Association for Cancer Research (AACR) Annual Meeting


Apr 14, 2023

MiNA Therapeutics Presents Late-Breaking Positive Phase 1b Data for MTL-CEBPA in Combination with an Anti-PD1 Checkpoint Inhibitor at the Annual American Association of Cancer Research (AACR) Meeting


Apr 14, 2023

Sapience Therapeutics to Present Late-Breaking Data on ST101 and ST316 at the American Association for Cancer Research (AACR) Annual Meeting 2023


Apr 14, 2023

Araris Biotech AG Presents Preclinical Data Highlighting Stable and Efficacious Low Drug-Load ADCs at American Association for Cancer Research (AACR) Annual Meeting 2023


Apr 13, 2023

Caris Life Sciences and Flare Therapeutics Announce Strategic Preferred Portfolio Partnership to Advance Flare's Precision Oncology Pipeline



Apr 13, 2023

Bold Therapeutics to Present Best-in-Class Phase 2 Metastatic Colorectal Cancer Data at AACR 2023


Apr 13, 2023

Turnstone Biologics to Present Preclinical Data for Selected TIL Therapy at the 2023 American Association for Cancer Research (AACR) Annual Meeting


Apr 13, 2023

Affini-T Therapeutics Announces Licensing Agreement with Leading Comprehensive Cancer Center to Expand Company’s Pipeline of Oncogenic Driver Programs


Apr 13, 2023

Affini-T Therapeutics Presents Preclinical Data from its Oncogenic Driver Program Targeting KRAS at the American Association for Cancer Research (AACR) Annual Meeting 2023


Apr 12, 2023

BPGbio Announces Oncology Drug Pipeline and Prostate Cancer Biomarker Developments at AACR



Apr 12, 2023

Synthekine Announces Presentations at AACR 2023 Annual Meeting Showcasing Next Series of Oncology Programs


Apr 12, 2023

Navrogen Presents Preclinical Data on NAV-001 Antibody-Drug Conjugate and NAV-003 Bispecific Programs at the 2023 American Association for Cancer Research Annual Meeting


Apr 12, 2023

CancerVAX CEO Ryan Davies Discusses Cancer Research with Leading Pediatric Hematologic Oncologist


Apr 11, 2023

Boundless Bio to Present at the Stifel 2023 Virtual Targeted Oncology Days


Apr 11, 2023

Virtuoso Therapeutics to Present Preclinical Findings on Three Best-in-Class Bispecific and ADC Programs at the 2023 American Association for Cancer Research (AACR) Annual Meeting



Apr 11, 2023

MAIA Biotechnology Reports Positive Topline Data from Part A Safety Lead-In of THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer


Apr 11, 2023

Elucida Oncology to Present New Clinical and Preclinical Data at the 2023 AACR Annual Meeting


Apr 10, 2023

Valitor to Present on the Potential for its Multivalent Polymer Technology to Expand the Therapeutic Index of Oncology Agents at the 2023 American Association for Cancer Research Annual Meeting


Apr 6, 2023

Accent Therapeutics to Present Data Supporting DHX9 Inhibition as a Novel Therapeutic Modality at American Association for Cancer Research (AACR) Annual Meeting 2023


Apr 6, 2023

Affini-T Therapeutics to Present Preclinical Data from its Oncogenic Driver Program Targeting KRAS at the American Association for Cancer Research (AACR) Annual Meeting 2023



Apr 5, 2023

Biotheryx Announces Research Collaboration and License Agreement with Incyte for Discovery of Targeted Protein Degraders for Novel Oncology Targets


Apr 4, 2023

Scorpion Therapeutics and Pierre Fabre Announce Collaboration and License Agreement to Co-Develop and Commercialize STX-721 and STX-241 for Patients with EGFR Mutant Non-Small Cell Lung Cancer


Apr 3, 2023

Scorpion Therapeutics Nominates STX-241 as Potentially Best-in-Class Fourth-Generation EGFR Inhibitor Development Candidate for the Treatment of Non-Small Cell Lung Cancer


Mar 31, 2023

Ablaze Pharmaceuticals Plans Development of Innovative GPC3 Targeted Radiopharmaceutical Therapy for Liver Cancer in Greater China USA - English APAC - English USA - English USA - Deutsch USA - español


Mar 31, 2023

Ablaze Pharmaceuticals Plans Development of Innovative GPC3 Targeted Radiopharmaceutical Therapy for Liver Cancer in Greater China USA - English APAC - English USA - Deutsch USA - Français USA - English USA - español



Mar 31, 2023

Ablaze Pharmaceuticals Plans Development of Innovative GPC3 Targeted Radiopharmaceutical Therapy for Liver Cancer in Greater China


Mar 31, 2023

Ablaze Pharmaceuticals compte développer une radiothérapie ciblée innovante ciblant le GPC3 et destinée à traiter le cancer du foie en Grande Chine USA - Français APAC - English USA - English USA - Deutsch USA - English USA - español


Mar 30, 2023

Trobix Bio Raises $3 Million from Chartered Group to Advance Precision Microbiome Oncology Therapeutics


Mar 29, 2023

Wugen to Present Data on WU-NK-101 at the American Association for Cancer Research (AACR) Annual Meeting 2023


Mar 29, 2023

Transcenta's Osemitamab (TST001) Targeting Claudin18.2 Granted Orphan Drug Designation for Treatment of Pancreatic Cancer



Mar 29, 2023

Synthetic mRNA Market for Cancer Treatment size to grow at a CAGR of 13.4% by 2029: Growth opportunities led by BioNTech SE, Moderna Inc., CureVac AG, eTheRNA immunotherapies NV - Brandessence Market Research


Mar 28, 2023

Morphogenesis Inc. Acquires TυHURA Biopharma’s First-in-Class Antibody Drug Conjugates (ADCs) Technology Designed to Overcome Acquired Resistance to Cancer Immunotherapy


Mar 27, 2023

OncoNano Medicine Presents Data from Phase 2 Pegsitacianine Study at Society of Surgical Oncology (SSO) 2023 International Congress on Surgical Cancer Care


Mar 24, 2023

HiberCell to Present Pre-clinical Data on its Novel GCN2 Activator and PERK Inhibitor Programs at the American Association for Cancer Research (AACR) Annual Meeting 2023


Mar 23, 2023

Macomics and Ono Pharmaceutical Partner to Discover and Develop Macrophage-targeting Antibody Therapy for the Treatment of Cancer



Mar 23, 2023

Anaveon announces presentation of a novel development compound at the 2023 American Association for Cancer Research Annual Meeting


Mar 22, 2023

Biosion bispecific antibody therapies to be featured at the American Association for Cancer Research (AACR) annual meeting 2023


Mar 21, 2023

RayzeBio Nominates Glypican-3 (GPC3) Targeted Radiopharmaceutical Therapy Drug Candidate for Treatment of Liver Cancer


Mar 21, 2023

Prestige Biopharma Receives FDA Fast Track Designation for PBP1510 in the Treatment of Pancreatic Cancer


Mar 20, 2023

CancerVAX CEO Ryan Davies Sits Down with Oncology Research Leader



Mar 17, 2023

CancerVax Universal Cancer Vaccine Being Developed by UCLA


Mar 16, 2023

Sapience Therapeutics Announces Late-Breaking Research Poster Presentations on ST101 and ST316 at the American Association for Cancer Research (AACR) Annual Meeting 2023


Mar 16, 2023

CancerVax Files Non-Provisional Patent for Universal Cancer Vaccine


Mar 16, 2023

ITM to Present Phase III COMPOSE Poster and Host Satellite Symposium on Radiotheranostics in NET cancer at ENETS Conference


Mar 15, 2023

Boundless Bio Announces Upcoming Presentation at the American Association for Cancer Research Annual Meeting 2023



Mar 15, 2023

Hummingbird Bioscience to Present Two Posters on HER3-Targeting Therapeutics at American Association for Cancer Research (AACR) Meeting 2023 USA - English APAC - English


Mar 15, 2023

OncoNano Medicine to Present at the American Association for Cancer Research (AACR) Annual Meeting 2023


Mar 15, 2023

Vivace Therapeutics to Unveil First Clinical Data for a Cancer Drug Targeting the Hippo Pathway


Mar 15, 2023

Sermonix Pharmaceuticals Announces E-Poster Presentation on I-SPY 2 Study of Neoadjuvant Lasofoxifene at St. Gallen International Breast Cancer Conference 2023


Mar 14, 2023

Eureka Therapeutics Licenses Promising Antibody Targeting Mesothelin from the National Cancer Institute



Mar 14, 2023

Araris Biotech AG to Present Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2023


Mar 14, 2023

Nitrase Therapeutics to Present at the 2023 American Association for Cancer Research Annual Meeting


Mar 9, 2023

Prestige Biopharma Develops First-in-Class PAUF-detecting Diagnostic Kit, a Powerful Tool for Early Detection of Pancreatic Cancer


Mar 9, 2023

Sermonix Pharmaceuticals Announces Initiation of Phase 3 ELAINE-3 Study of Lasofoxifene Plus Abemaciclib in Pre- and Post-Menopausal Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer with an ESR1 Mutation as Detected by Guardant Health’s Guardant360 CDx Liquid Biopsy


Mar 8, 2023

Nature Paper from PACT Pharma and UCLA Highlights How Patients with Cancer Respond Differently to Anti-PD-1 Therapy



Mar 8, 2023

Tessa Therapeutics Enters into Cooperative Research and Development Agreement (CRADA) with the U.S. National Cancer Institute


Mar 7, 2023

Shorla Oncology Announces U.S. FDA Approval of Nelarabine Injection for the Treatment of T-cell Leukemia


Mar 7, 2023

MAIA Biotechnology Doses First Patients in Europe in Ongoing Phase 2 Trial (THIO-101) Evaluating THIO for Non-Small Cell Lung Cancer Treatment


Mar 7, 2023

NanOlogy Granted a US Patent for Its Investigational Drugs in Combination with Immune Checkpoint Inhibitors in the Treatment of Cancer


Mar 6, 2023

Therapeutic Solutions International Announces Plans to Initiate Breast Cancer Clinical Trial Using FloraStilbene™ Immune Stimulator Through Res Nova Bio Subsidiary



Mar 6, 2023

Hummingbird Bioscience Exercises Its Option to License the Clinical Trial Results from Cancer Research UK to Support Further Development of HMBD-001


Mar 6, 2023

Cantex and Miami Cancer Institute Announce FDA Clearance for a Clinical Trial Investigating Azeliragon Combined with Stereotactic Radiosurgery for the Treatment of Brain Metastases


Mar 6, 2023

Bicara Therapeutics Announces Oversubscribed $108 Million Series B Financing to Advance Clinical-Stage Pipeline of Dual-Action Biologics to Treat Cancer


Mar 6, 2023

AKTIS ONCOLOGY TO PARTICIPATE IN THE COWEN 43RD ANNUAL HEALTHCARE CONFERENCE


Mar 6, 2023

Virion Therapeutics Presents Promising Preclinical Cancer Data When Using a Novel Genetically Encoded Checkpoint Modifier-Based Immunotherapy



Mar 6, 2023

Sermonix’s Lasofoxifene Improves Vaginal/Vulvar Symptoms Relative to Fulvestrant in ELAINE 1 Study of Postmenopausal Women with Locally Advanced or Metastatic ER+/HER2- Breast Cancer and an ESR1 Mutation


Mar 2, 2023

Flamingo Therapeutics and Dynacure Announce Merger to Create Leading RNA Therapeutics Company Focused on Clinical Oncology


Mar 2, 2023

Kartos Therapeutics Appoints Dr. Srdan Verstovsek as Chief Medical Officer


Mar 2, 2023

SiSaf and the University of Leipzig Partner to Develop Bio-Courier Targeted miRNA for the Treatment of Pancreatic Cancer


Feb 28, 2023

Incyclix Bio Announces FDA Clearance of Investigational New Drug Application for INX-315 in Patients with Advanced or Metastatic Cancer



Feb 23, 2023

Peel Therapeutics Closes New Financing Round and Expands Board of Directors to Support Evolution-Based Medicines for Cancer and Inflammation


Feb 23, 2023

Accutar Biotechnology Announces First Patient Dosed in China with AC0176 in Phase 1 Study in Prostate Cancer


Feb 17, 2023

Scientists at Macomics and University of Edinburgh Map Out the Discoveries of a New Class of Tumour Associated Immune Cells Revealing Opportunities to Develop Novel Cancer Treatments


Feb 14, 2023

enGene announces poster presentation containing interim Phase 1 clinical trial data at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium


Feb 14, 2023

Propella Therapeutics Announces Presentation of Updated Phase 1/2a Data of PRL-02 for the Treatment of Advanced Prostate Cancer at 2023 ASCO Genitourinary (GU) Cancers Symposium



Feb 9, 2023

Artios Announces Initiation of Phase 2 Randomized Trial for ATR Inhibitor ART0380 plus Gemcitabine in Patients with Platinum Resistant Ovarian Cancer


Feb 7, 2023

Palleon Pharmaceuticals to Present at the Guggenheim Healthcare Talks Oncology Day


Feb 7, 2023

Ankyra Therapeutics Announces Collaboration to Evaluate ANK-101 in Early Clinical Trials Focused on Lung Cancer


Feb 6, 2023

RNAimmune mRNA Cancer Vaccine Program Accepted for Oral Presentation at the 2023 AACR Annual Meeting


Feb 3, 2023

Mnemo Therapeutics and Institut Curie Announce Two Key Publications in Science Immunology Highlighting Novel Approach to Identify Unknown, Therapeutically Relevant Cancer-Specific Targets USA - English France - Français



Feb 2, 2023

Flare Therapeutics to Present at Guggenheim Healthcare Talks 2023 Oncology Day


Feb 1, 2023

Ratio Therapeutics Announces $20M Series A Financing to Advance Targeted Radiotherapies for Cancer Treatment


Jan 31, 2023

Istari Oncology Announces First Patient Dosed in the Non-Muscle-Invasive Bladder Cancer (NMIBC) Substudy of the LUMINOS-103 Basket Trial Evaluating Lerapolturev Monotherapy


Jan 31, 2023

Myeloid Therapeutics to Present at the Guggenheim Healthcare Talks 2023 Oncology Day


Jan 30, 2023

Therapeutic Solutions International Spin Off Res Nova Bio Announces Recruitment of President and Chief Executive Officer



Jan 26, 2023

Sapience Therapeutics to Present at the Guggenheim Healthcare Talks 2023 Oncology Day


Jan 25, 2023

KSQ Therapeutics Announces Ono Pharmaceutical Co., Ltd. is Acquiring Multiple Research-Stage Oncology Programs Identified with KSQ’s CRISPRomics Platform Technology


Jan 21, 2023

Wugen Presents Data on WU-NK-101 in Combination with Cetuximab in Preclinical Models of Advanced Colorectal Cancer (CRC) at ASCO Gastrointestinal Cancers Symposium


Jan 19, 2023

Tallac Therapeutics Appoints Kevin N. Heller, M.D., as Chief Medical Officer


Jan 19, 2023

LinKinVax and Gustave Roussy Collaborate on a Phase I/IIa HPV.DCVax Clinical Trial for the Treatment of Patients with HPV-Positive Oropharyngeal Cancer



Jan 19, 2023

Foundation Medicine Announces Global Collaboration with Boehringer Ingelheim to Advance Biliary Tract Cancer Care


Jan 17, 2023

Transcenta to Present "Trial in Progress" at ASCO-GI 2023 for TST001 (Osemitamab) Combination with Nivolumab, with or without Chemotherapy in Advanced G/GEJ Cancer


Jan 11, 2023

Testicular Cancer - Global Pipeline Insights, 2022: Featuring Sanofi, Seagen, BioNTech, Context Therapeutics and Leadartis - ResearchAndMarkets.com


Jan 9, 2023

Avenge Bio Announces Dosing of First Patient in Phase 1/2 Clinical Trial Evaluating AVB-001 for the Treatment of Ovarian Cancer


Jan 9, 2023

Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies



Jan 5, 2023

Akamis Bio Announces $30 Million Financing, Provides Clinical Program Update and Relaunches with Name Change from PsiOxus Therapeutics


Jan 5, 2023

ArsenalBio Announces First Patient Dosed in Phase 1 Clinical Trial of AB-1015 in Development as a Treatment for Ovarian Cancer


Jan 5, 2023

Inspirna Announces Interim Data from Phase 1b/2 Study of Abequolixron (RGX-104) in Relapsed or Refractory Lung Cancer


Jan 5, 2023

Nouscom Announces Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate NOUS-209 in combination with KEYTRUDA (pembrolizumab) in a Phase 2 Randomized Trials in dMMR/MSI-High Metastatic Colorectal Cancer


Jan 4, 2023

AKTIS ONCOLOGY TO PRESENT AT THE 41ST ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE



Jan 3, 2023

Elucida Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference


Jan 3, 2023

ZielBio Appoints Alan Bash CEO as Company Advances Oncology Therapeutics


Dec 27, 2022

CG Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference


Dec 27, 2022

ZielBio Receives Orphan Drug Designation for ZB131 for the Treatment of Pancreatic Cancer


Dec 27, 2022

Insilico Medicine Nominates Preclinical Candidate Targeting KAT6A for ER+/HER2- Breast Cancer Therapy with End-to-End AI Engine



Dec 21, 2022

Anocca secures EUR 25 million from the European Investment Bank (EIB) to support clinical development of next-generation T-cell therapies for cancer


Dec 20, 2022

MAIA Biotechnology Holds Successful Pre-IND Meeting with FDA for Planned US Expansion of THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer


Dec 20, 2022

Kite to Acquire Tmunity Therapeutics to Pursue Next Generation CAR T-Cell Therapy Advancements in Cancer


Dec 20, 2022

iOnctura awarded EUR17.5 million funding from the EIC Accelerator for clinical development of novel pancreatic cancer therapy


Dec 19, 2022

Sermonix Shares Two Recently Presented Posters Evaluating ESR1 Mutations in Circulating Tumor DNA From Patients With ER+/HER2- Metastatic Breast Cancer Who Were Treated With Lasofoxifene



Dec 15, 2022

MimiVax Announces Positive Final Data from the Phase IIa Study of SurVaxM for Newly Diagnosed Glioblastoma Published Today in the Journal of Clinical Oncology


Dec 14, 2022

Geneos Therapeutics Announces Another Complete Response in Ongoing Clinical Trial of Personalized Therapeutic Cancer Vaccination in Second Line Advanced Liver Cancer


Dec 13, 2022

MAIA Biotechnology Expands Phase 2 THIO-101 Trial to Europe


Dec 13, 2022

PharmaJet Partner Immunomic Therapeutics Receives FDA Fast Track Designation for pDNA Vaccine for Skin Cancer


Dec 13, 2022

Therabest and Glycotope to assess Therabest’s iPSC-derived NK cell product TB-100 in combination with Glycotope’s GT-00AxIL15 immuno-cytokine for development in triple negative breast cancer



Dec 12, 2022

ICHNOS SCIENCES PRESENTS DATA SUPPORTING THREE ONCOLOGY ASSETS AT ASH 2022 ANNUAL MEETING


Dec 12, 2022

Onchilles Pharma Nominates First Drug Development Candidate Leveraging Neutrophil Biology for the Treatment of Cancer


Dec 9, 2022

Sermonix Shares Two Posters at SABCS 2022 on ER+/HER2- Metastatic Breast Cancer Patient Survey About Knowledge of NGS and ESR1 Mutations, Quality of Life Concerns


Dec 8, 2022

Oncolytics Biotech's Chinese Development Partner Adlai Nortye Presents Interim Clinical Data Further Demonstrating the Anti-Cancer Activity of Pelareorep-Paclitaxel Combination Therapy in HR+/HER2- Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium USA - English USA - English USA - English Deutschland - Deutsch


Dec 8, 2022

iOnctura initiates Phase Ib pancreatic cancer trial of next-generation autotaxin inhibitor IOA-289



Dec 8, 2022

Scorpion Therapeutics Presents Preclinical Data for Potential Best-in-Class PI3Kα Inhibitor at San Antonio Breast Cancer Symposium


Dec 8, 2022

Sermonix Pharmaceuticals Announces Poster Presentation on Phase 1 Ethnobridging Study of Lasofoxifene at the 12th AACR-JCA Joint Conference: Breakthroughs in Cancer Research — Translating Knowledge Into Practice


Dec 8, 2022

Intensity Therapeutics' Reports Up to 100% Tumor Necrosis After One Dose of Lead Asset, INT230-6 in Phase 2 INVINCIBLE Neoadjuvant Breast Cancer Study at the San Antonio Breast Cancer Symposium (SABCS)


Dec 8, 2022

Context Therapeutics Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer


Dec 8, 2022

Oncolytics Biotech's Chinese Development Partner Adlai Nortye Presents Interim Clinical Data Further Demonstrating the Anti-Cancer Activity of Pelareorep-Paclitaxel Combination Therapy in HR+/HER2- Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium



Dec 6, 2022

Systems Oncology to Present Positive Preclinical Data for SERA2 at J.P. Morgan 41st Annual Healthcare Conference


Dec 6, 2022

Candel Therapeutics RandD Day Presentations Spotlight its Advanced Pipeline and Capabilities to Develop Novel Viral Immunotherapies for Patients with Cancer


Dec 1, 2022

Researchers from Insilico Medicine, University of Copenhagen, and University of Chicago unravel molecular secrets hidden in premature aging diseases and cancer using AI


Nov 30, 2022

Propanc Biopharma Concludes PRP Could Become an Effective Chemosensitizer Agent Against Pancreatic Cancer


Nov 29, 2022

AIVITA Biomedical Chief Medical Officer Dr. Robert O. Dillman to Deliver Keynote and Chair Cancer Immunotherapy Track at World Vaccine and Immunotherapy Congress



Nov 29, 2022

Turnstone Biologics Enters Cooperative Research and Development Agreement with the National Cancer Institute to Study TIL Therapy in Combination with Viral Immunotherapy


Nov 28, 2022

Strand Therapeutics Announces Series A1 Bringing Total Round to US$97 Million


Nov 22, 2022

Jeito Capital co-leads EUR 50 million financing in CatalYm, a clinical-stage biopharma company developing novel immunotherapies for patients with cancer


Nov 21, 2022

Scorpion Therapeutics to Present Preclinical Data for Potential Best-in-Class Mutant-Selective PI3Kα Inhibitor at San Antonio Breast Cancer Symposium


Nov 21, 2022

FogPharma Announces $178 Million Series D Financing to Advance Pipeline of First-in-Class Helicon Polypeptide Therapeutics Targeting Major Cancer Drivers



Nov 17, 2022

Sermonix Pharmaceuticals Announces Four Abstracts Accepted for Presentation at 2022 San Antonio Breast Cancer Symposium


Nov 17, 2022

ImmunoMet Therapeutics Announces First Patient Dosed in a Phase 1b Trial of IM156 in Pancreatic Cancer


Nov 15, 2022

Propanc Biopharma’s CSO Predicts PRP Could Enhance Therapeutic Effects of Immune Checkpoint Therapy for Pancreatic Cancer


Nov 15, 2022

CG Oncology Raises $120 Million in Oversubscribed Series E Financing to Advance Clinical-Stage Urologic Oncology Pipeline


Nov 15, 2022

AUM Biosciences Receives Human Research Ethics Committee Approval to Commence Phase II Clinical Trial of AUM001 for Treatment of Metastatic Colorectal Cancer in Australia



Nov 15, 2022

Nouscom Announces First Patient Dosed in Phase 2 Randomized Trial with NOUS-209, an 'off-the shelf' Neoantigen Cancer Immunotherapy in dMMR/MSI-High Metastatic Colorectal Cancer


Nov 14, 2022

OncoNano Medicine Announces New Preclinical Data for ON-BOARD™ Platform for Delivery of Bispecific T Cell Engagers and a Therapeutic Cytokine at the Society for Immunotherapy of Cancer (SITC) Annual Meeting


Nov 11, 2022

NanOlogy Completes Enrollment in Phase 2a Trial of Intratumoral LSAM-PTX with SOC in Patients with Nonoperable Lung Cancer


Nov 11, 2022

Tallac Therapeutics Presents Data for Two, First-in-Class Toll-like Receptor 9 Agonist Antibody Conjugates at the Society for Immunotherapy of Cancer 37th Annual Meeting


Nov 10, 2022

HotSpot Therapeutics Presents Preclinical Data from CBL-B Program at 2022 Society for Immunotherapy of Cancer Annual Meeting



Nov 10, 2022

PACT Pharma Reports Data From First Clinical Study Using CRISPR to Substitute a Gene in Patients' Immune Cells to Treat Cancer


Nov 10, 2022

Immune-Onc Therapeutics to Present Trial in Progress Poster for Phase 1 Study of IO-202 in Patients with Advanced Solid Tumors at the Society for Immunotherapy of Cancer Annual Meeting


Nov 10, 2022

Myeloid Therapeutics Presents Update On Myeloid Cell Programming Technologies, Including Non-Human Primate Proof-Of-Concept Data Delivering in vivo mRNA TROP-2 Targeting CAR (MT-302) at Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting


Nov 10, 2022

Asher Bio Presents New Preclinical Data at SITC 2022 Further Supporting Advancement of AB248 and AB821 as Highly Differentiated Cis-targeted Cancer Immunotherapies


Nov 10, 2022

Ankyra Therapeutics Presents Positive Preclinical Data Supporting Advancement of ANK-101 into Clinical Studies for Treatment of Solid Tumors



Nov 10, 2022

Imvax Presents Preclinical Data at SITC 2022 Supporting Mechanism of Action and Anti-tumor Activity of its Immunotherapy Platform Across Multiple Tumor Types


Nov 10, 2022

Galvanize Therapeutics Presents Clinical Data Using Pulsed Electric Field (PEF) Energy for Non-Small Cell Lung Cancer


Nov 10, 2022

CG Oncology Presents New Phase 2 Data With CG0070 in Combination With KEYTRUDA (pembrolizumab) in Non-Muscle Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guérin


Nov 10, 2022

OncoNano Medicine Announces Pre-Clinical Data for Dual-Activating STING agonist at the Society for Immunotherapy of Cancer (SITC) Annual Meeting


Nov 10, 2022

Aulos Bioscience Presents Initial Data From First-in-Human Phase 1/2 Clinical Trial of Computationally Designed Antibody AU-007 at 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting



Nov 10, 2022

CytoImmune Therapeutics to Present Preclinical Data Highlighting Potential of Novel TRACK-NK Cells to Selectively Target and Kill Hematologic and Solid Tumor Cancer Cells


Nov 10, 2022

EvolveImmune Therapeutics Reports Preclinical Data Highlighting Deep and Durable Anti-Tumor Efficacy with EV-104 in Presentation at 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)


Nov 10, 2022

Umoja Biopharma Presents New Preclinical Data on its Integrated In Vivo CAR T and Engineered Induced Pluripotent Stem Cell Platform Technologies at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting


Nov 8, 2022

Turnstone Biologics to Present Preclinical Data From Novel TIL Therapy Demonstrating Tumor-Reactive T-Cell Selection at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting


Nov 8, 2022

Immune-Onc Therapeutics Appoints Two New Members to its Board of Directors



Nov 7, 2022

Nouscom's Personalized Neoantigen Cancer Immunotherapy NOUS-PEV Demonstrates Promising Safety, Immunogenicity and Anti-tumor Activity in Solid Tumors


Nov 7, 2022

Aleta Biotherapeutics Receives Innovation Passport Designation for Biologic CAR T-Cell Therapy Engager ALETA-001


Nov 7, 2022

Navrogen Enters into CRADA with The U.S. National Cancer Institute for the Clinical Development of NAV-001, an Anti-Mesothelin Antibody-Drug Conjugate


Nov 7, 2022

Hummingbird Bioscience Announces Two HMBD-002 Poster Presentations at the Society for Immunotherapy of Cancer 2022 Annual Meeting


Nov 7, 2022

Geneos Therapeutics Announces Positive Clinical Data for Personalized Therapeutic Cancer Vaccines in Ongoing Liver Cancer Trial



Nov 7, 2022

Bicara Therapeutics Presents Preclinical Data for Precision Immunocytokine, BCA356, at Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting


Nov 7, 2022

Affini-T Therapeutics to Present Preclinical Data from its Lead Programs Targeting KRAS G12V at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting


Nov 7, 2022

Therapeutic Solutions International Spin-Off Res Nova Bio Collaborates with Veltmeyer MD Inc. to Provide Breast Cancer Patients Access to Novel Cancer Immunotherapy


Nov 3, 2022

Elucida Oncology to Present at the Piper Sandler 34th Annual Healthcare Conference


Nov 2, 2022

Basilea announces sale of preclinical oncology program to Twentyeight-Seven Therapeutics



Nov 2, 2022

HiberCell to Present Preclinical Data from Novel GCN2 Activator and PERK Inhibitor Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting


Nov 1, 2022

Carisma Therapeutics Announces Multiple Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer 37th Anniversary Annual Meeting


Oct 31, 2022

Nitrase Therapeutics Presented Data on Role of Novel Nitrases in Regulating Known and Important Cancer Targets at EORTC-NCI-AACR Symposium


Oct 28, 2022

Flare Therapeutics Presents Comprehensive Real-World Data in Advanced and Metastatic Urothelial Cancer in Support of Therapeutic Targeting of PPARG at 2022 EORTC-NCI-AACR Symposium


Oct 27, 2022

Triumvira Immunologics to Present Clinical and Preclinical Updates at Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting



Oct 27, 2022

Therapeutic Solutions International Announces Launch of Cancer Immunotherapy Spin-Off Res Nova Bio, Inc.


Oct 26, 2022

Flare Therapeutics Presents Preclinical Data that Show Potential of Novel PPARG Inhibitors to Treat Urothelial Cancer at 2022 EORTC-NCI-AACR Symposium


Oct 24, 2022

CG Oncology to Present New Phase 2 Data with CG0070 in Combination with KEYTRUDA (pembrolizumab) in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin at SITC 2022


Oct 24, 2022

EvolveImmune Therapeutics Presents Promising Preclinical Data from Novel Costimulatory T Cell Engager Platform at American Association for Cancer Research (AACR) Special Conference on Tumor Immunology and Immunotherapy


Oct 21, 2022

Elpiscience Announces Five Poster Presentations at Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting



Oct 20, 2022

AUM Biosciences, a Global Biotechnology Company Developing Precision Oncology Therapeutics, Announces Plans to Become a Public Company via Merger with Mountain Crest Acquisition Corp. V


Oct 19, 2022

Avenge Bio to Present Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting


Oct 19, 2022

PIC Therapeutics Completes $35 Million Series A Financing to Develop Treatments for Drug-Resistant Breast Cancer


Oct 19, 2022

Umoja Biopharma to Present Three Posters Data on its Integrated In Vivo CAR T and ShRED Platform Technologies at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting


Oct 18, 2022

Eureka Therapeutics Announces License with the National Cancer Institute to Advance GPC2 ARTEMIS T Cell Therapy for Neuroblastoma



Oct 18, 2022

Istari Oncology Announces Presentation of Clinical Responses from LUMINOS- 102, an ongoing Phase 2 Trial of Lerapolturev in anti-PD-1 Refractory Metastatic Melanoma at the Society for Melanoma Research (SMR) 2022 Congress


Oct 14, 2022

Phanes Therapeutics announces FDA IND clearance for PT217, an anti-DLL3/anti-CD47 bispecific antibody being developed for patients with small cell lung cancer and other neuroendocrine cancers


Oct 13, 2022

Odyssey Therapeutics Announces Oversubscribed $168 Million Series B Financing


Oct 12, 2022

Propanc Biopharma’s CEO to Attend 43rd Meeting of the European Organization of Research and Treatment of Cancer (EORTC), Dec 15 - 17


Oct 12, 2022

Tavros Therapeutics and Vividion Therapeutics Announce Strategic Collaboration to Discover and Enhance Targeted Oncology Programs



Oct 12, 2022

Derm-Biome Pharmaceuticals, Inc. reports positive preclinical data in melanoma and squamous cell carcinoma, initiates a program aimed at advancing topical therapies for skin cancer to the clinic


Oct 12, 2022

Capstan Therapeutics Announces Appointment of Athena Countouriotis, M.D., as Board Chair and Strengthens Leadership Team with Key Appointment


Oct 11, 2022

Palleon to Present on Phase 1/2 E-602 Bi-Sialidase Trial Design at Society for Immunotherapy of Cancer (SITC) Annual Meeting


Oct 6, 2022

Shasqi Scientific Advisor Carolyn Bertozzi Awarded Nobel Prize for the Development of Click Chemistry


Oct 5, 2022

HotSpot Therapeutics to Present Preclinical Data from CBL-B Program at 2022 Society for Immunotherapy of Cancer Annual Meeting



Oct 5, 2022

OncoNano Medicine to Present Data on Novel Development Candidates at the Society for Immunology of Cancer (SITC) Annual Meeting


Oct 4, 2022

Model Medicines Announces Launch of Oncology Programs with Multiple AI-Discovered Compounds Demonstrating Drug-Like Activity for Two High Value, Difficult to Drug, Oncogenic and Epigenetic Targets


Oct 4, 2022

Sapience Therapeutics Awarded SBIR Phase 2 Grant from National Cancer Institute (NCI) of the National Institutes of Health (NIH) for ST101 in Breast Cancer


Oct 3, 2022

Therapeutic Solutions International Identifies CD103 Expressing Dendritic Cells and Exosomes Thereof as Novel Mechanism for JadiCell Mesenchymal Stem Cell Mediated Lung Protection


Sep 29, 2022

Imvax Presents New Data on Personalized Whole-Tumor Derived Immunotherapeutic Platform at 2022 International Cancer Immunotherapy Conference



Sep 29, 2022

MAIA Biotechnology to Present at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics


Sep 29, 2022

Biosplice Therapeutics Announced New Clinical Data for Cirtuvivint (SM08502) at the European Society for Clinical Oncology Meeting


Sep 29, 2022

With the Establishment of India Entity, Mickey Mikitani, Co-CEO of Rakuten Medical Visits Respected Medical Institutions in India


Sep 29, 2022

Meliora Therapeutics Raises $11M Seed Financing to Develop First Mechanism Of Action Atlas in Oncology


Sep 27, 2022

Scribe Therapeutics Announces Research Collaboration with Sanofi to Accelerate Breakthrough CRISPR-based Cell Therapies for Cancer



Sep 27, 2022

SEngine Precision Medicine Announces New Non-Small Cell Lung Cancer Study at Johns Hopkins University


Sep 26, 2022

CatalYm Receives FDA IND Clearance to Expand Development of Visugromab in Advanced Cancer Patients into the U.S.


Sep 26, 2022

Qu Biologics to Launch Phase 2B Clinical Trial to Assess Reduction of Postoperative Immune Suppression and Disease Progression in Patients with Late-Stage Colorectal Cancer


Sep 22, 2022

Imvax to Present New Data on Tumor-Derived Immunotherapy Platform at 2022 International Cancer Immunotherapy Conference


Sep 21, 2022

Abpro Finalizes Strategic Partnership with Celltrion for Worldwide Development and Commercialization of a Cancer Treatment Bispecific Antibody



Sep 21, 2022

Genelux Corporation Initiates a Pivotal Phase 3 Trial, Evaluating Olvi-Vec for the treatment of Platinum-Resistant/Refractory Ovarian Cancer


Sep 21, 2022

NKGen Biotech Announces Publication in Journal of Cancer Research and Cellular Therapeutics on Durable Response for SNK01 in Advanced Sarcoma


Sep 20, 2022

Elicio Therapeutics Receives $2.8 Million Grant from the Gastro-Intestinal Research Foundation (GIRF) to Fund Research for Two Therapeutic Cancer Vaccines


Sep 19, 2022

AKTIS ONCOLOGY APPOINTS SHULAMIT RON-BIGGER AS CHIEF OPERATING OFFICER


Sep 19, 2022

Sapience Therapeutics Announces Publication Showcasing the Mechanism of Action and Anti-tumor Activity of ST101, a Novel and Selective Peptide Antagonist of C/EBPβ, in Molecular Cancer Therapeutics



Sep 19, 2022

OncoNano Medicine to Present at Cantor Fitzgerald Oncology and HemOnc Conference


Sep 18, 2022

Bugworks Research Inc. et Cytecare Cancer Hospitals annoncent leur collaboration pour accélérer le développement de thérapies d'immuno-oncologie de pointe France - Français USA - English Deutschland - Deutsch USA - English


Sep 16, 2022

EXUMA Biotech to Present at the 2022 Cancer Immunology and Immunotherapy Conference and to Participate in the 7th Annual CAR-TCR Summit


Sep 15, 2022

Integral Molecular Licenses Claudin 18.2 Monoclonal Antibodies to CARTEXELL for Oncology Cell Therapies


Sep 14, 2022

Sermonix Pharmaceuticals Shares Details of First-Ever Known Durable Complete Clinical Response in a Metastatic ER+/HER2- Breast Cancer Patient With an ESR1 Mutation After Prior CDK4/6 Inhibitor Treatment Via Single-Agent Hormonally Based Regimen



Sep 13, 2022

RayzeBio Advances RYZ101, a Targeted Radiopharmaceutical Delivering Actinium-225, into Clinical Development for Two Cancer Indications


Sep 13, 2022

RayzeBio Propels Forward with $418 Million Raised Since Inception to Advance Targeted Radiopharmaceuticals for Cancer


Sep 13, 2022

Sermonix Pharmaceuticals Announces Results of Phase 2 Study of Lasofoxifene vs. Fulvestrant in Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2- Breast Cancer and an ESR1 Mutation


Sep 12, 2022

Nimbus Therapeutics Closes $125M Private Financing to Advance Clinical Programs in Autoimmune Diseases and Oncology


Sep 12, 2022

Enterome presents further efficacy data on its new generation therapeutic cancer vaccine EO2401 at ESMO Congress, demonstrating ability of OncoMimics™ antigens to generate positive clinical outcome



Sep 12, 2022

Transcenta Releases Encouraging Interim Safety and Efficacy Data of the TST001 (Osemitamab) and Chemotherapy Combination Expansion Cohort for First Line Claudin18.2 Positive Gastric Cancer at ESMO Congress 2022


Sep 10, 2022

Wugen Presents Preclinical Data on WU-NK-101 in Solid Tumor Models at the European Society for Medical Oncology (ESMO) Congress 2022


Sep 10, 2022

Bicara Therapeutics Presents New Data from Ongoing Phase 1/1b Trial of Lead First-in-Class Bifunctional Program, BCA101, at the European Society for Medical Oncology (ESMO) Congress 2022


Sep 9, 2022

Rhizen Pharmaceuticals AG Announces Upcoming Data Presentations at ESMO 2022 for Its Clinical Stage Assets; Tenalisib in Locally Advanced/ Metastatic Breast Cancer and RP12146 in Multiple Solid Tumors


Sep 9, 2022

Privo Technologies, Inc. Awarded $2M Direct-to-Phase II Contract from the National Cancer Institute for PRV311 Treatment of Cervical Cancer



Sep 8, 2022

Hummingbird Bioscience Announces Trial in Progress Poster Presentation at the European Society for Medical Oncology Congress 2022


Sep 8, 2022

Osmol Therapeutics Announces Appointment of Teresa Bitetti, President, Global Oncology Business Unit at Takeda Pharmaceuticals, to the Board of Directors


Sep 8, 2022

Propella Therapeutics Announces Presentation of Phase 1/2 Data of PRL-02 for the Treatment of Advanced Prostate Cancer at ESMO Congress 2022


Sep 7, 2022

Lutris Pharma Reports Positive Top-Line Results From the Open Label Part 1 and Double Blinded Part 2 of Its Phase 1/2 Trial of LUT014 to Treat Radiation Dermatitis in Patients with Breast Cancer USA - English USA - English USA - English


Sep 7, 2022

InxMed Announces First Patient Dosed in Phase 2 Pivotal Study of IN10018 In Patients with Platinum-Resistant Recurrent Ovarian Cancer



Sep 7, 2022

Nitrase Therapeutics Appoints Arun Kashyap, Ph.D., to Lead its Recently Launched Oncology Programs as Senior Vice President of Oncology


Sep 7, 2022

SEngine Precision Medicine Partners with Vincere Cancer Center to Increase Access for First Responders to Get Personalized Cancer Treatments via the PARIS Test


Sep 7, 2022

Lutris Pharma Reports Positive Top-Line Results From the Open Label Part 1 and Double Blinded Part 2 of Its Phase 1/2 Trial of LUT014 to Treat Radiation Dermatitis in Patients with Breast Cancer USA - English USA - English India - English Israel - English


Sep 6, 2022

Nodus Oncology launches, founded by Cumulus Oncology and in partnership with the Lead Discovery Center, to focus on developing first and best-in-class molecules inhibiting novel DNA damage response targets


Sep 6, 2022

Triumvira Immunologics to Present Interim Clinical Data from Ongoing Phase 1/2 Trial with T Cell Therapy TAC01-HER2 at European Society for Medical Oncology 2022 Congress



Sep 6, 2022

Enterome to present updates on EO2401, its first-in-class OncoMimics™ therapeutic cancer vaccine targeting solid tumors, at ESMO Congress 2022


Sep 6, 2022

MAIA Biotechnology to Present Design of THIO-101 Trial at European Society for Medical Oncology (ESMO) Congress 2022


Sep 6, 2022

NKGen Biotech To Present SNK01 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2022


Sep 4, 2022

Wugen Announces Presentation of WU-NK-101 Preclinical Data at the European Society for Medical Oncology (ESMO) Congress 2022


Aug 29, 2022

NEXT-GENERATION EGFR TKI H002 FROM REDCLOUD BIO COMPLETES FIRST DOSE IN NON-SMALL CELL LUNG CANCER



Aug 25, 2022

AKTIS ONCOLOGY RAISES $84 MILLION TO ADVANCE NOVEL TARGETED ALPHA RADIOPHARMACEUTICALS


Aug 23, 2022

Aktis Oncology Announces Actinium-225 Supply Agreements with Leading Isotope Producers


Aug 23, 2022

NorthStar Medical Radioisotopes Announces Supply Agreement with Aktis Oncology, Inc. for Alpha-emitting Therapeutic Radioisotope Actinium-225 (Ac-225)


Aug 22, 2022

PanTher Therapeutics Awarded $14.2M from CPRIT to Advance Targeted, Localized and Sustained Cancer Treatment


Aug 22, 2022

Bright Peak Therapeutics Announces the Appointment of Cancer Immunotherapy Leader Jon Wigginton, M.D., as President of Research and Development



Aug 19, 2022

Accutar Biotechnology Receives NMPA Clearance of IND Application for AC0176 in Prostate Cancer


Aug 18, 2022

Sirnaomics Doses the First Patient in Phase I/II Clinical Study of RNAi Therapeutic STP705 for Treatment of Facial Squamous Cell Skin Cancer In Situ


Aug 18, 2022

Innovative Cellular Therapeutics (ICT) Announces First Patient Enrolled for the Company’s Phase I Trial of GCC19CART for Relapsed/Refractory Metastatic Colorectal Cancer


Aug 17, 2022

Philadelphia-based Biotech Company AUM LifeTech Awarded $400,000 NCI/NIH Grant to Advance Their Lung Cancer Immunotherapy Program Using RNA-Targeting Gene Therapy with Checkpoint Inhibitors


Aug 16, 2022

Propanc Biopharma Receives Notice of Allowance for Proenzyme Compositions to Treat Cancer from the European Patent Office



Aug 10, 2022

Artios initiates Phase 2 study of Polθ Inhibitor ART4215 in Combination with PARP Inhibitor Talazoparib in BRCA Deficient Breast Cancer


Aug 3, 2022

Eureka Therapeutics Announces Publication of Crystal Structure of TCR Mimic Redirected T Cells Targeting Alpha-Fetoprotein (AFP) for Liver Cancer


Aug 2, 2022

MAIA Biotechnology Receives FDA Orphan Drug Designation for THIO for the Treatment of Small-Cell Lung Cancer (SCLC)


Aug 1, 2022

NanOlogy Publishes Results from a Phase 1/2 Clinical Trial of Large Surface Area Microparticle Docetaxel in High-Risk Non-Muscle Invasive Bladder Cancer


Jul 28, 2022

SEngine Precision Medicine closes Series A bringing total financing to $19M enabling continued advancement of personalized cancer treatments



Jul 28, 2022

Step Pharma Progresses into Oncology Clinical Trials with STP938, the World’s Most Advanced CTPS1 Inhibitor


Jul 28, 2022

NeoPhore Enters Three Year Research Collaboration with World Leading Oncologist's Lab at Major US Cancer Center


Jul 28, 2022

Propanc Biopharma’s CSO Reflects on Unique Anti-Cancer Effects of PRP Discovered Over Past Decade


Jul 27, 2022

Transcenta to Present Interim Safety and Efficacy Data of the TST001 and Chemotherapy Combination Expansion Cohort for Claudin18.2 Positive First Line Gastric Cancer at ESMO Congress 2022


Jul 27, 2022

BridGene Biosciences Announces $38.5 Million Series B Financing to Further Develop Its Next Generation Chemoproteomics Platform and First-in-Class Oncology Drugs



Jul 26, 2022

Sirnaomics Receives IND Clearance from the Taiwan Ministry of Health and Welfare for Phase I Clinical Study of RNAi Therapeutic STP705 for Liver Cancer Treatment


Jul 19, 2022

Propanc Biopharma Successfully Produces Synthetic Recombinant Trypsinogen Via POP1 Joint Research and Drug Discovery Program


Jul 18, 2022

MAIA Biotechnology Doses First Patient With THIO in Phase 2 Trial (THIO-101) for Non-Small Cell Lung Cancer


Jul 12, 2022

Propanc Biopharma’s CEO Believes Lead Asset Could Unlock Value as PRP Advances to Phase I, First-In-Human Study in Advanced Cancer Patients


Jul 11, 2022

Inspirna Raises $50 Million in Series D Financing



Jul 11, 2022

Anthos Therapeutics Announces that Abelacimab has Received FDA Fast Track Designation for the Treatment of Thrombosis Associated with Cancer


Jul 7, 2022

Kernal Biologics Announces $25M Series A Financing to Advance its mRNA 2.0 Technology for Oncology


Jul 6, 2022

Turnstone Biologics and Moffitt Cancer Center Announce Strategic Alliance to Advance Next-Generation TIL Therapies for Solid Tumors


Jul 6, 2022

Zenith Epigenetics Announces Start of Several National Cancer Institute (NCI)-Sponsored Oncology Clinical Trials


Jul 5, 2022

ArriVent Biopharma Announces First Patient Enrolled in Global Phase 1b Trial of Furmonertinib in Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR or HER2 Mutations



Jun 30, 2022

Phanes Therapeutics' PT886 granted Orphan Drug Designation for the treatment of pancreatic cancer by the FDA


Jun 29, 2022

ReCode Therapeutics to Expand Next-Generation Delivery Platform and Diversify Genetic Medicines Pipeline with Oversubscribed Series B Financing Totaling $200M


Jun 29, 2022

Ornithine Decarboxylase (ODC) Inhibitor Pipeline Insight Report 2022 Featuring Orbus Therapeutics, Aminex Therapeutics, Genzyme, Nippon Kayaku, and Cancer Prevention Pharmaceuticals - ResearchAndMarkets.com


Jun 28, 2022

Inspirna to Present Phase 1b RGX-202-01 Clinical Trial Data at the 2022 ESMO World Congress on Gastrointestinal Cancer


Jun 28, 2022

Araris Biotech AG to Present at the H.C. Wainwright Preclinical Cancer Drug Discovery Virtual Conference



Jun 27, 2022

US FDA Approves Prestige Biopharma’s IND for Phase 1/2a Trial of First-in-Class Pancreatic Cancer Treatment, PBP1510


Jun 27, 2022

Treos Bio Announces First Patient Dosed in Phase 2 Trial of PolyPEPI1018 in Combination with Roche’s PD-L1-Inhibitor for the Treatment of Metastatic Colorectal Cancer


Jun 22, 2022

Nutcracker Therapeutics Bolsters Leadership with Chief Operating Officer and Other Key Hires, Reveals Oncology Pipeline


Jun 22, 2022

Propanc Biopharma’s CSO Hails Dostarlimab’s Impressive Results Whilst Acknowledging More Work to Be Done in the Fight Against Cancer


Jun 21, 2022

Phanes Therapeutics' PT217 receives Orphan Drug Designation for small cell lung cancer from the FDA



Jun 21, 2022

Zenith Epigenetics Triple Negative Breast Cancer Clinical Data Highlighted in an Oral Discussion at the American Society of Clinical Oncology Conference (ASCO)


Jun 16, 2022

Panbela Therapeutics, Inc. Closes Acquisition of Cancer Prevention Pharmaceuticals, Inc.


Jun 16, 2022

Team Led by Boundless Bio Scientific Founders Receives $25M Award to Better Understand Extrachromosomal DNA (ecDNA) Through Cancer Grand Challenges


Jun 15, 2022

WuXi ATU and Wugen Announce Manufacturing Partnership to Expedite the Delivery of Novel Cell Cancer Immunotherapies


Jun 14, 2022

MAIA Biotechnology, Inc. Announces Research Collaboration with Nationwide Children’s Hospital to Evaluate THIO in Combination with Standard-of-Care Cancer Therapies



Jun 14, 2022

AVM Biotechnology Awarded $2 Million National Cancer Institute SBIR Phase II Grant from the National Institutes of Health to Advance AVM0703 in Cancer


Jun 14, 2022

NCI/NIH Award $2 Million to Immunicom to Initiate Clinical Trial Evaluating Breakthrough Immunopheresis LW-02 Molecular Subtractive Therapy in Refractory ER+/Her2- Breast Cancer


Jun 14, 2022

Propanc Biopharma’s PRP to Target 80 – 90% of Cancer Cases


Jun 9, 2022

Clinique d'Oncologie 16 Novembre Becomes First Site in Africa to Deploy Varian's Ethos Therapy System for Adaptive Cancer Treatment USA - English France - Français


Jun 7, 2022

EpimAb Biotherapeutics Announces U.S. FDA Clearance of IND Application for Phase Ib/II Trial of EMB-01 in Combination with Tagrisso for Non-Small Cell Lung Cancer



Jun 7, 2022

AUM Biosciences Announces FDA IND Authorization for Global Phase 2 Trial of Selection Translation Inhibitor AUM001 in Colorectal Cancer


Jun 6, 2022

Nouscom Announces Positive Phase 1 Data of NOUS-209, an 'off-the-shelf' Neoantigen Cancer Immunotherapy for the Treatment of dMMR/MSI-H Solid Tumors, at ASCO 2022


Jun 6, 2022

Enterome presents proof-of-concept immune response data and first clinical data from Phase 1/2 trial with EO2401, a first-in-class OncoMimics™ therapeutic cancer vaccine for glioblastoma, at ASCO 2022


Jun 6, 2022

Apexigen Announces Nature Medicine Publication and ASCO Presentation on the Phase 2 PRINCE Trial Showcasing Distinct Biosignatures in Metastatic Pancreatic Cancer Patients Treated with Sotigalimab and/or Nivolumab in Combination with Chemotherapy


Jun 4, 2022

CG Oncology Presents New Clinical Data on Two Ongoing Programs at The American Society of Clinical Oncology (ASCO) 2022 Annual Meeting



Jun 3, 2022

Bicara Therapeutics Presents Data from Dose Escalation Portion of Ongoing Phase 1/1b Trial of Lead Bifunctional Program, BCA101, at the American Society of Clinical Oncology 2022 Annual Meeting


Jun 3, 2022

Elucida Oncology to Present at Two Upcoming Conferences


Jun 2, 2022

Scorpion Therapeutics Announces Discovery Scientific Advisory Board


Jun 2, 2022

Immunicom Clinical Trial Data at ASCO 2022 Show Immunopheresis LW-02 Column is Safe and Effectively Depletes Soluble TNF-α Receptors in Patients with Advanced Triple Negative Breast Cancer


Jun 2, 2022

Nitrase Therapeutics Expands Pipeline to Include Oncology Programs and Adds Seasoned Cancer Experts to Scientific Advisory Board



Jun 2, 2022

BOEHRINGER INGELHEIM ENTERS GLOBAL LICENSING AGREEMENT TO DEVELOP AND COMMERCIALIZE INNOVATIVE ANTIBODIES FROM A*STAR FOR TARGETED CANCER THERAPIES


Jun 1, 2022

OncoNano Medicine Appoints Kartik Krishnan, M.D., Ph.D., as Chief Medical Officer


Jun 1, 2022

Transcenta Releases Phase I Clinical Data of TST001 in Combination with CAPOX as the First Line Treatment of Advanced and Metastatic G/GEJ Cancer at ASCO 2022


Jun 1, 2022

Propanc Biopharma Believes PRP Reduced Toxicity Will Impact Cancer Patient Lives Significantly


Jun 1, 2022

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. and Levena Biopharma, a Sorrento Company, are to Present Positive Clinical Progress of A166, an Anti-HER2 ADC, in Treating Locally Advanced or Metastatic HER2-Positive Breast Cancer Patients at the ASCO 2022 Annual Meeting



Jun 1, 2022

Elucida Oncology to Present Trials in Progress Poster for Phase 1/2 Study of ELU001 in Patients with Advanced, Recurrent, or Refractory Cancers Overexpressing FRα at 2022 American Society of Clinical Oncology Annual Meeting


Jun 1, 2022

Accutar Biotechnology Announces Fast Track Designation Granted by FDA to AC0176 for the Treatment of Metastatic Castration-Resistant Prostate Cancer


Jun 1, 2022

Astellas and GO Therapeutics Enter into Strategic Research and License Agreement to Develop Novel Antibodies for Immuno-Oncology


May 31, 2022

Sermonix to Present Updated Data from ELAINE-2 Clinical Trial of Lasofoxifene in Combination with Abemaciclib in Women with Locally Advanced or Metastatic ER+/HER2− Breast Cancer and an ESR1 Mutation after Progression on Prior Therapies at the 2022 ASCO Annual Meeting


May 31, 2022

Eureka Therapeutics and City of Hope Treat First Patient with GPC3 Targeting ARTEMIS T Cells (ECT204) for Advanced Liver Cancer



May 30, 2022

Nature Cancer Publishes the Collaborative Study Results by Transcenta and Shanghai Jiao Tong University Scientists


May 29, 2022

InxMed IN10018 at ASCO 2022 demonstrates robust efficacy in patients with platinum-resistant recurrent ovarian cancer


May 27, 2022

Nouscom to Present Full Phase 1 Data of NOUS-209, an 'off-the-shelf' Neoantigen Cancer Immunotherapy for the Treatment of dMMR/MSI-H Solid Tumors, at ASCO 2022


May 26, 2022

Biotheryx to Present Preclinical Data for Its Dual Protein Degrader BTX-1188 at the 2022 American Society of Clinical Oncology Annual Meeting


May 26, 2022

Inspirna to Present Phase 1b RGX-202-01 Clinical Trial Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting



May 26, 2022

Laekna Therapeutics Announces Dosing of First Patients in the U.S. and China in Phase Ib/III Study of Afuresertib in Combination with Fulvestrant in HR+/HER2- Breast Cancer


May 26, 2022

Innovative Cellular Therapeutics (ICT) Announces Presentation at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting


May 26, 2022

Worldwide Cancer Cachexia Industry to 2027 - Featuring Aphios, Artelo Biosciences and AVEO Pharmaceuticals Among Others - ResearchAndMarkets.com


May 26, 2022

Propanc Biopharma Presents 100 Years of Clinical Evidence for “Novel” Enzyme Therapeutic Approach to Treat Cancer


May 24, 2022

Biocytogen/Eucure Biopharma to Present Clinical Data from YH003 (anti-CD40 mAb) and YH001 (anti-CTLA-4 mAb) Trials at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting USA - English España - español France - Français Deutschland - Deutsch



May 24, 2022

HiberCell to Present Posters on Novel Candidates Odetiglucan and HC-7366 at the 2022 Annual American Society of Clinical Oncology Meeting


May 23, 2022

Salubris Biotherapeutics Announces New Pipeline Advancements and Appointment of Chief Medical Officer


May 20, 2022

Sirnaomics will present clinical study results and development strategy for Cancer RNA Therapeutics at the 2022 Pre-ASCO China Summit


May 19, 2022

Enterome to present world first clinical data with EO2401, its first-in-class off-the-shelf OncoMimics™ therapeutic cancer vaccine, at ASCO 2022


May 19, 2022

Myeloid Therapeutics Enters Into Agreement with Acuitas Therapeutics for Lipid Nanoparticle (LNP) System, Enabling the First-Ever Delivery of mRNA-Encoded CARs Directly to Humans



May 18, 2022

Propanc Biopharma Undertaking PRP Manufacturing and Development for Human Use


May 17, 2022

Nouscom Announces Janssen Receives US FDA IND Clearance for VAC85135, an 'Off-The-Shelf' Cancer Immunotherapy Developed using Nouscom's Proprietary Viral Vector Platform


May 16, 2022

ITM to Host Scientific Precision Oncology Symposium in Parallel to the ASCO Annual Meeting on Friday, June 03, 2022


May 16, 2022

CG Oncology Presents Additional Phase 2 Data with CG0070 in Combination with KEYTRUDA (pembrolizumab) in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin


May 11, 2022

Propanc Biopharma Offers a Novel Way to Stop Cancer



May 10, 2022

MOMA Therapeutics Announces $150 Million Series B Financing


May 10, 2022

Zenith Epigenetics Announces Initiation of a Phase 2b Triple Negative Breast Cancer (TNBC) Clinical Trial


May 8, 2022

Umoja Biopharma Presents Data on its iPSC-Based Cell Therapy Platform at the American Association for Cancer Research (AACR) Annual Meeting 2022


May 6, 2022

Elucida Oncology to Present at the Bank of America 2022 Healthcare Conference


May 5, 2022

AUM Biosciences Announces Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate AUM001 in Combination with KEYTRUDA (pembrolizumab) in Colorectal Cancer



May 4, 2022

Rhizen Pharmaceuticals AG Announces Promising Interim Data Presentation From an Ongoing Phase II Study of Tenalisib (RP6530) in Locally Advanced or Metastatic Breast Cancer Patients At ESMO Breast Cancer Meeting 2022


May 3, 2022

NanOlogy Publishes Results from a Phase 1/2 Clinical Trial of its Topical Investigational Drug in the Treatment of Cutaneous Metastases of Breast Cancer


May 3, 2022

Levena Biopharma, A Sorrento Company, Announces Positive Clinical Data for Its Out-Licensed A166 Product Candidate, A Third-Generation Anti-HER2-ADC, In Treating Heavily Pretreated HER2-Positive Breast Cancer Patients


May 2, 2022

CERo Therapeutics’ Multifunctional CER T Cells Synergize with Standard-of-Care Small Molecule Anti-Tumor Inhibitors Across Hematologic and Solid Tumor Models


Apr 28, 2022

HiberCell Announces First Patients Dosed in Phase 2 Clinical Trial of Odetiglucan in Combination with KEYTRUDA (pembrolizumab) in Adult Patients with Metastatic, Hormone-Refractory Breast Cancer



Apr 28, 2022

Sermonix Announces Abstracts Accepted for Presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting


Apr 27, 2022

Inspirna Announces Phase 1b RGX-202 Clinical Trial Data Selected for Poster Presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting


Apr 27, 2022

Catamaran Bio Appoints Cherry Thomas, MD, as Chief Medical Officer


Apr 26, 2022

Flare Therapeutics Appoints Adrian Jubb as Chief Medical Officer


Apr 25, 2022

AI Therapeutics Announces the Acquisition of Novel Cancer Drug Candidate EC-8042 (AIT-102)



Apr 25, 2022

Portage Biotech Enters Cooperative Research and Development Agreement with U.S. National Cancer Institute and Stimunity


Apr 21, 2022

OncXerna Therapeutics Announces Journal of Clinical Oncology Publication Featuring Phase 1b Data of Navicixizumab Plus Paclitaxel in Ovarian Cancer


Apr 21, 2022

Innovative Cellular Therapeutics (ICT) Announces Data Presentation at the American Association for Cancer Research (AACR) Annual Meeting


Apr 20, 2022

Immune-Onc Therapeutics Announces the Selection of Clinical Development Candidate IO-106, a First-in-Class Myeloid and Stromal Checkpoint Inhibitor Targeting LAIR1


Apr 19, 2022

Innovative Cellular Therapeutics (ICT) Receives FDA Fast Track Designation for GCC19CART, its Lead Solid Tumor Candidate, in the Treatment of Patients with Relapsed or Refractory Metastatic Colorectal Cancer



Apr 19, 2022

Immune-Onc Therapeutics to Participate in the Raymond James LILRB/ILT Symposium on Myeloid Checkpoint Therapeutics in Cancer


Apr 18, 2022

Ankyra Therapeutics Announces Cooperative Research and Development Agreement with the National Cancer Institute


Apr 14, 2022

Be Bio Closes $130 Million Financing to Pioneer Engineered B Cells, a New Class of Cellular Medicines


Apr 13, 2022

Phosplatin Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of PT-112 for Thymoma and Thymic Carcinoma in Collaboration with National Cancer Institute


Apr 13, 2022

CG Oncology Presents Interim Phase 2 Data with CG0070 in Combination with KEYTRUDA (pembrolizumab) in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin



Apr 13, 2022

EdiGene Enters Research Collaboration With Peking University Cancer Hospital to Advance the Development of Targeted Therapy for Colorectal Cancer


Apr 13, 2022

InxMed FAK Inhibitor IN10018 Received Breakthrough Therapy Designation by the China National Medical Products Administration for Platinum-Resistant Ovarian Cancer


Apr 13, 2022

Propanc Biopharma’s Management Explains Why They Believe Cancer Patients Are Likely to Respond to PRP Treatment


Apr 12, 2022

Chimeron Bio Enters Into Manufacturing Agreement With FUJIFILM Diosynth Biotechnologies to Advance its RNA Oncology Candidates


Apr 12, 2022

Trishula Therapeutics Announces Promising Early Phase 1b Data of TTX-030, an Anti-CD39 Antibody, in Combination with Chemoimmunotherapy as First-Line Treatment for Locally Advanced or Metastatic Gastric Cancer/GEJ Cancer



Apr 11, 2022

Circle Pharma Announces Presentation at the American Association for Cancer Research 2022 Annual Meeting


Apr 11, 2022

MiNA Therapeutics Presents Proof of Mechanism Data on MTL-STING as a Novel Cancer Immunotherapy


Apr 11, 2022

Phosplatin Therapeutics Reports on PT-112's Selective Effects and Immunogenic Cell Death in Human Prostate Cancer Cell Models at the AACR Annual Meeting 2022


Apr 11, 2022

InventisBio Reported Promising Phase I Study Results of a Novel KRAS G12C Inhibitor D-1553 in Cancer Patients


Apr 11, 2022

PACT Reports New Data on First-of-its-Kind Personalized Neoantigen Platform for Adoptive T Cell Therapies at American Association for Cancer Research (AACR) Annual Meeting 2022



Apr 11, 2022

Vivace Therapeutics Presents New Preclinical Data Highlighting Strong Synergistic Activity for Combination of VT3989 and Osimertinib at American Association for Cancer Research (AACR) Annual Meeting 2022


Apr 11, 2022

Nouscom Announces New Translational Phase 1 Data of NOUS-209, an 'off-the-shelf' Neoantigen Cancer Vaccine for the Treatment of MSI-H Solid Tumors, at AACR 2022


Apr 11, 2022

Ribon Therapeutics Announces Presentations at the American Association for Cancer Research 2022 Annual Meeting


Apr 11, 2022

Sapience Therapeutics Presents Late-Breaking Data at AACR 2022 Demonstrating the Potential of Targeting Intracellular Interactions to Drug Well-Validated Cancer Pathways


Apr 10, 2022

Gennao Bio Presents Promising New Results from its Gene Monoclonal Antibody (GMAB) Platform at the American Association for Cancer Research (AACR) 2022 Annual Meeting



Apr 10, 2022

Myeloid Therapeutics Presents Late-Breaking Data at AACR 2022 Demonstrating the Ability of its ATAK™ Receptors and in vivo Delivery of mRNA to Attack Cancer by Immune Reprogramming


Apr 10, 2022

Triumvira Immunologics to Present Two Posters Covering Ongoing Phase 1/2 Solid Tumor Trial and New Preclinical Gastric Cancer Data at AACR Annual Meeting 2022


Apr 10, 2022

Myeloid Therapeutics Presents Late-Breaking Data at AACR 2022 Demonstrating the Ability of its ATAK Receptors and in vivo Delivery of mRNA to Attack Cancer by Immune Reprogramming


Apr 9, 2022

PIC Therapeutics to Present Pre-Clinical Data on eIF4E Program to Address Breast Cancer Drug Resistance at AACR Annual Meeting 2022


Apr 8, 2022

Boundless Bio Presents Data on the Novel Discovery of the Association Between Extrachromosomal DNA (ecDNA) and Replication Stress at the American Association for Cancer Research Annual Meeting 2022



Apr 8, 2022

Carisma Therapeutics to Present Engineered Cell Therapy Data at The American Association for Cancer Research Annual Meeting


Apr 8, 2022

HotSpot Therapeutics Presents Pre-Clinical Data on CBL-B Program at American Association for Cancer Research Annual Meeting 2022


Apr 8, 2022

Immunomic Therapeutics Reports Preclinical Data on Its MCPγV-LT and Her2/Neu DNA Vaccines at the American Association for Cancer Research (AACR) Annual Meeting 2022


Apr 8, 2022

Qihan Biotechnology Presents Preclinical Data at American Association for Cancer Research Annual Meeting 2022


Apr 8, 2022

Immune-Onc Therapeutics Makes Two Presentations of IO-108, a Novel Clinical-Stage Myeloid Checkpoint Inhibitor Targeting LILRB2 (ILT4), at the American Association for Cancer Research (AACR) 2022 Annual Meeting



Apr 8, 2022

T-knife Therapeutics Announces New TCR-T Program Targeting KRAS G12V and Presents Data at the American Association for Cancer Research (AACR) Annual Meeting


Apr 8, 2022

BioMed Leaders: Sunshine Biopharma, PharmaDrug, Blue Water Vaccines, and MedAvail; Visionary CEOs Advancing Healthcare, with Vaccines, Cancer Therapeutics, and Affordable Pharmaceuticals


Apr 8, 2022

Primmune Therapeutics Presents Data from Phase 1 Study Evaluating PRTX007 in Healthy Volunteers at the 2022 American Association for Cancer Research (AACR) Annual Meeting


Apr 8, 2022

Pyxis Oncology Announces Preclinical Data on Anti-Siglec-15 BSI-060T (PYX-106) Presented by Biosion, Inc. at the 2022 American Association for Cancer Research (AACR) Annual Meeting


Apr 8, 2022

Araris Biotech AG Presents Preclinical Data Highlighting Anti-CD79b ADC Program and Late-Breaking Data on Nectin-4 ADC at the American Association for Cancer Research (AACR) 2022 Annual Meeting



Apr 7, 2022

Synthekine Announces Multiple Poster Presentations Showcasing Its Three Distinct Cytokine Engineering Platforms at American Association for Cancer Research (AACR) 2022 Annual Meeting


Apr 7, 2022

REDCLOUD BIO TO PRESENT PRECLINICAL DATA OF NEXT-GENERATION EGFR TKI H002 AT ANNUAL MEETING OF AMERICAN ASSOCIATION OF CANCER RESEARCH


Apr 7, 2022

LTZ Therapeutics Secures $17 Million Pre-Series A Financing for Immunotherapy Development to Treat Cancer and Other Complex Diseases


Apr 6, 2022

Lutris Pharma Completes Enrollment of Part Two of its Phase 1/2 Trial of LUT014 To Treat Radiation Dermatitis in Patients with Breast Cancer USA - English USA - English USA - English


Apr 6, 2022

AffyImmune Therapeutics to Present Poster at American Association for Cancer Research Annual Meeting



Apr 6, 2022

Linnaeus Therapeutics Awarded $4,000,000 SBIR Phase 2 Bridge Award by the National Cancer Institute to Advance LNS8801 for the Treatment of Cutaneous and Uveal Melanoma


Apr 6, 2022

Tegmine Therapeutics Announces Collaboration with Alloy Therapeutics to Advance Solid Tumor Treatment


Apr 6, 2022

Propanc Biopharma’s CEO Expresses Concern Over Disruption to Cancer Care During Global Pandemic


Apr 6, 2022

Lutris Pharma Completes Enrollment of Part Two of its Phase 1/2 Trial of LUT014 To Treat Radiation Dermatitis in Patients with Breast Cancer USA - English Israel - English


Apr 6, 2022

Notch Therapeutics Welcomes Deepika Rajesh as VP, Stem Cell Biology and Developmental Immunology



Apr 5, 2022

Nouscom Announces AACR 2022 Late-Breaking Presentation of Translational Phase 1 Data of NOUS-209, an 'off-the-shelf' Neoantigen Cancer Immunotherapy for the Treatment of MSI-H Solid Tumors


Apr 4, 2022

Bright Peak Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting


Apr 4, 2022

Bright Peak Therapeutics kündigt mehrere Präsentationen auf der Jahrestagung der American Association for Cancer Research (AACR) an


Apr 4, 2022

Elucida Oncology’s Lead Clinical Candidate ELU001 to Be Featured in Two Abstracts at the American Association for Cancer Research Annual Meeting


Apr 4, 2022

Vivace Therapeutics to Present New Data from Preclinical Combination Studies of VT3989 and Osimertinib at American Association for Cancer Research (AACR) Annual Meeting 2022



Apr 1, 2022

Accutar Biotechnology Receives NMPA Clearance of IND Application for AC0682 in ER-Positive Breast Cancer


Mar 31, 2022

Immunomic Therapeutics Announces Two Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022


Mar 30, 2022

Transcenta Announces Presentation of Preclinical Data of TST005 at the 2022 American Association for Cancer Research (AACR) Annual Meeting


Mar 30, 2022

NERx Biosciences to Present New Data Highlighting Their Pre-clinical Pipeline of Drugs Targeting the DNA Damage Response at American Association For Cancer Research Annual Meeting in April


Mar 30, 2022

NERx Biosciences to Present New Data Highlighting Their Pre-clinical Pipeline of Drugs Targeting the DNA Damage Response at American Association For Cancer Research Annual Meeting



Mar 30, 2022

Accutar Biotechnology Announces First Patient Dosed with AC0176 in Phase 1 Study in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)


Mar 29, 2022

Shorla Oncology Appoints Dennis Purcell as Chairman of the Board of Directors


Mar 29, 2022

Biosion licenses BSI-060T (anti-Siglec-15) to Pyxis Oncology


Mar 28, 2022

Alpha Tau Medical Announces Full Year 2021 Financial Results and Provides Corporate Update USA - English USA - English


Mar 28, 2022

Primmune Therapeutics to Present Interim Clinical Data from Phase 1 Study Evaluating PRTX007 at the 2022 American Association for Cancer Research (AACR) Annual Meeting



Mar 25, 2022

ITM Provides n.c.a. Lutetium-177 as Long-Term Supplier for Recently Approved Novel Radiotherapeutic in Metastatic Prostate Cancer


Mar 24, 2022

Oncolytics Biotech Partner Adlai Nortye Advances Chinese Bridging Trial of Pelareorep-Paclitaxel Combination Treatment in Breast Cancer to Final Dosing Cohort


Mar 24, 2022

Geneos Therapeutics Secures $17 Million in Series A2 Financing to Advance Personalized Cancer Immunotherapy Platform


Mar 24, 2022

Oncolytics Biotech Partner Adlai Nortye Advances Chinese Bridging Trial of Pelareorep-Paclitaxel Combination Treatment in Breast Cancer to Final Dosing Cohort USA - Français USA - English USA - English Norge - Norsk Sverige - Svenska USA - Nederlands Suomi - Suomeksi


Mar 23, 2022

Catalys Pacific Launches Kirilys Therapeutics as a Multi-asset Precision Oncology Company



Mar 23, 2022

Virtuoso Therapeutics to Present Preclinical Findings on Two Best-in-Class Bispecific Programs at the 2022 American Association for Cancer Research (AACR) Annual Meeting


Mar 22, 2022

Pyxis Oncology to Host Corporate Update Conference Call and Webcast on March 29, 2022


Mar 22, 2022

ITM Receives EUR 33 Million Equity Investment to Advance Precision Oncology Pipeline of Targeted Radiopharmaceuticals


Mar 22, 2022

KSQ Therapeutics to Present Data at the American Association for Cancer Research (AACR) 2022 Annual Meeting


Mar 22, 2022

Affini-T Therapeutics Completes $175 Million Financing Co-Led by Vida Ventures and Leaps by Bayer to Advance Groundbreaking T Cell Therapies for Solid Tumor Patients with Oncogenic Driver Mutations



Mar 22, 2022

Ribon Therapeutics Initiates First-in-Human Phase 1 Clinical Study of RBN-3143 for the Treatment of Atopic Dermatitis


Mar 22, 2022

Propanc Biopharma Receives Notice of Allowance for Method to Treat Cancer Stem Cells from the US Patent and Trademark Office


Mar 21, 2022

Vivacitas Oncology Appoints Harvard Professor of Medicine Dr. David Reardon, MD to the Company's Neuro-Oncology Medical Advisory Board


Mar 21, 2022

Volastra Therapeutics Announces Drug Discovery Collaboration with Bristol Myers Squibb


Mar 21, 2022

Biond Biologics Announces Oral Presentation for BND-67, an Inhibitor of CD28 Shedding, a Potential Novel Resistance Mechanism to Anti PD-1 Therapy, at the American Association for Cancer Research (AACR) 2022 Annual Meeting USA - English USA - English



Mar 21, 2022

Transcenta Announces Global Clinical Collaboration with Bristol Myers Squibb to Evaluate TST001 in Combination with Opdivo in Patients with Locally Advanced or Metastatic Gastric / Gastroesophageal Junction Cancer France - Français USA - English Deutschland - Deutsch


Mar 21, 2022

Transcenta Announces Global Clinical Collaboration with Bristol Myers Squibb to Evaluate TST001 in Combination with Opdivo in Patients with Locally Advanced or Metastatic Gastric / Gastroesophageal Junction Cancer


Mar 21, 2022

Biond Biologics Announces Oral Presentation for BND-67, an Inhibitor of CD28 Shedding, a Potential Novel Resistance Mechanism to Anti PD-1 Therapy, at the American Association for Cancer Research (AACR) 2022 Annual Meeting


Mar 17, 2022

Shasqi to Present on SQ3370 and CAPAC Platform Expansion at the American Association for Cancer Research (AACR) 2022 Annual Meeting


Mar 17, 2022

Shasqi to Present on SQ3370 and CAPAC™ Platform Expansion at the American Association for Cancer Research (AACR) 2022 Annual Meeting



Mar 16, 2022

Phanes Therapeutics Announces Three Upcoming Presentations at the 2022 American Association for Cancer Research (AACR) Annual Meeting


Mar 16, 2022

KayoThera, Inc. Raises $8 Million in Series A Financing Led by Accelerator Life Science Partners to Develop Novel Cancer Immunotherapeutics


Mar 15, 2022

EXUMA Biotech to Present Preclinical Data from its Subcutaneous CAR-TaNK and In Vivo CAR Cell and Gene Therapy Programs at the American Association for Cancer Research Annual Meeting


Mar 15, 2022

Highlight Therapeutics to present at the American Association for Cancer Research (AACR) Annual Meeting 2022


Mar 15, 2022

KAHR Announces Publication of Preclinical Data Indicating Monotherapy and Combination Treatment Potential of its Investigational Anti-CD47 Fusion Protein USA - English USA - English



Mar 15, 2022

PharmaJet Partner Immunomic Therapeutics Initiates Clinical Trial of DNA Vaccine for Skin Cancer


Mar 15, 2022

KAHR Announces Publication of Preclinical Data Indicating Monotherapy and Combination Treatment Potential of its Investigational Anti-CD47 Fusion Protein


Mar 14, 2022

SIWA Therapeutics Announces Promising Results in New Pancreatic Cancer Study


Mar 11, 2022

The Result of the Phase 3 Study for Prestige BioPharma’s Herceptin Biosimilar, HD201(Tuznue), Published in JAMA Oncology


Mar 11, 2022

Curebase and Blue Note Therapeutics Collaborate on Home-based Clinical Trial of Prescription Digital Therapeutics to Help People with Cancer Manage their Health



Mar 10, 2022

BioCurity Pharmaceuticals Inc. ('BioCurity' or ‘Company’) Expanding Patent Portfolio Successes for Supportive Cancer Drugs Designed to Prevent Radiation Therapy Side Effects


Mar 10, 2022

BioCurity Pharmaceuticals Inc. ('BioCurity' or ‘Company’) Announces Presentation at ACRO Summit 2022 on Sensitizing Head and Neck Cancer to Radiation Using the Company’s Cerium Oxide Nanoparticles


Mar 10, 2022

NeoImmuneTech to Present Two Posters at American Association for Cancer Research Annual Meeting


Mar 10, 2022

Phosplatin Therapeutics Presents on PT-112 at the 2022 AACR Annual Meeting: Selective Intracellular Effects Leading to Immunogenic Cell Death (ICD) in Prostate Cancer Cell Models


Mar 10, 2022

DepYmed and Monash Biomedicine Discovery Institute to Study the Role of a New Generation of PTP1B Inhibitors against a Novel Intracellular Checkpoint in Cancer



Mar 10, 2022

ExCellThera announces first patient treated in Phase I/II trial of ECT-001 cell therapy for pediatric patients with high risk blood cancer


Mar 10, 2022

OncoNano Medicine to Present at the American Association for Cancer Research (AACR) Annual Meeting 2022


Mar 10, 2022

Scenic Biotech Announces $31 Million Financing to Progress Pipeline of Genetic Modifiers in Cancer and Rare Diseases


Mar 9, 2022

Twist Bioscience and Kriya Sign Agreement to Discover Novel Antibodies for Applications in Oncology Using Gene Therapy


Mar 9, 2022

Boundless Bio Announces Upcoming Presentation at the American Association for Cancer Research Annual Meeting 2022



Mar 9, 2022

Immune-Onc Therapeutics Announces Preclinical and Clinical Poster Presentations for IO-108, a Novel Myeloid Checkpoint Inhibitor Targeting LILRB2 (ILT4), at the American Association for Cancer Research (AACR) 2022 Annual Meeting


Mar 9, 2022

Seneca Therapeutics Announces Publication of AACR Abstract Demonstrating Systemic Anti-Tumor Immune Response in Syngeneic Pancreatic Murine Model


Mar 9, 2022

Transcenta Presented Safety / Tolerability and Preliminary Anti-tumor Activity Data in Gastric and Pancreatic Cancers of TST001 Monotherapy from China Phase I Clinical Trial at the 2022 International Gastric Cancer Congress


Mar 9, 2022

Sapience Therapeutics Announces Multiple Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022


Mar 9, 2022

Frontier Medicines Announces Oral Presentation on Dual-Acting Inhibitors of the Active and Inactive Forms of KRAS G12C at the American Association for Cancer Research (AACR) Annual Meeting



Mar 9, 2022

Araris Biotech AG to Present Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2022


Mar 9, 2022

Boehringer Ingelheim and OSE Immunotherapeutics To Present Biomarker Analyses From the Phase 1 Clinical Trial With First-in-Class SIRPα Inhibitor BI 765063 in Advanced Solid Tumors


Mar 8, 2022

Palleon Pharmaceuticals Announces First Patient Dosed in Phase 1/2 Study of Lead Glyco-Immunology Drug Candidate for Oncology


Mar 8, 2022

Exscientia to Highlight Precision Medicine Platform and Pipeline Data at the American Association of Cancer Research Annual Meeting 2022


Mar 8, 2022

HotSpot Therapeutics to Present Pre-Clinical Data on CBL-B Program at American Association for Cancer Research Annual Meeting 2022



Mar 8, 2022

Preclinical Data of Prestige Biopharma’s First-in-Class Pancreatic Cancer Treatment, PBP1510, Presented in ESMO TAT 2022


Mar 8, 2022

Lyell Immunopharma Announces Upcoming Presentation on LYL797 at the American Association for Cancer Research (AACR) 2022 Annual Meeting


Mar 8, 2022

Gennao Bio Announces Oral Presentation at the American Association for Cancer Research (AACR) 2022 Annual Meeting


Mar 7, 2022

Nectin Therapeutics Announces $5.4 Million Investment from Cancer Focus Fund to Support Phase 1 Study of First-in-Class Anti-PVR Targeted Immunotherapy USA - English USA - English


Mar 7, 2022

Nectin Therapeutics Announces $5.4 Million Investment from Cancer Focus Fund to Support Phase 1 Study of First-in-Class Anti-PVR Targeted Immunotherapy USA - English Israel - English



Mar 3, 2022

HiberCell to Present Clinical Applications of Odetiglucan and the Role of Beta-Glucan in Cancer Treatment


Mar 3, 2022

Elucida Oncology to Present at Two Upcoming Scientific Conferences


Mar 2, 2022

Prokarium Exercises Option for an Exclusive Worldwide License for the Use of Salmonella Immunotherapy in the Treatment of Bladder Cancer


Mar 2, 2022

Epsilogen Announces Completion of Oversubscribed £30.75 Million ($41.20 Million) Series B Financing


Mar 2, 2022

REDCLOUD BIO ANNOUNCES FDA ACCEPTANCE OF IND APPLICATION FOR NEXT-GENERATION EGFR INHIBITOR H002 IN NON-SMALL CELL LUNG CANCER



Mar 2, 2022

Propanc Biopharma’s Cancer Stem Cell Technology Offers Renewed Hope to Achieve a Total Victory Against Metastatic Cancer


Mar 1, 2022

Actuate Therapeutics Announces First Patient Enrolled in Phase 2 Clinical Trial of Elraglusib Plus Retifanlimab as Investigational First Line Therapy for Patients With Advanced Pancreatic Cancer


Mar 1, 2022

NextRNA Launches with $56 Million in Funding to Bring Transformative Non-Coding RNA-Directed Medicines to Patients


Feb 28, 2022

Innovent Biologics and AnHeart Therapeutics Receive NMPA Breakthrough Designation for Taletrectinib in ROS1-Positive Non-Small Cell Lung Cancer


Feb 28, 2022

Elpiscience Announces First Patient Dosed in Phase 1/2 Clinical Study of ES104 for Treatment of Colorectal Cancer



Feb 27, 2022

Transcenta Announces First Patient Dosed in Phase IIa Study of Claudin18.2 Monoclonal Antibody TST001 Combined with Cisplatin and Gemcitabine for the First Line Treatment of Biliary Tract Cancer


Feb 25, 2022

Privo Technologies, Inc. Awarded $2.5M from National Cancer Institute for its Intraoperative Treatment of Solid Tumors


Feb 24, 2022

GI Innovation Signs MoU With Cellkey for Biomarker Joint Research to Develop Next-generation Innovative Immuno-oncology


Feb 22, 2022

Boundless Bio Appoints Klaus Wagner, M.D., Ph.D., as Chief Medical Officer


Feb 22, 2022

Zenith Epigenetics Announces Dosing of First Cancer Patient with a Combination of ZEN-3694 + Bristol Myers Squibb’s Immune Checkpoint Inhibitor OPDIVO



Feb 22, 2022

Panbela Therapeutics, Inc. to Acquire Cancer Prevention Pharmaceuticals, Inc.


Feb 22, 2022

Cumulus Oncology Secures £4.1m ($5.6m) Investment Led by Eos Advisory


Feb 17, 2022

Edison Oncology Announces Treatment of First Patient in Orotecan (irinotecan HCI oral solution) Phase I/IIa Clinical Trial for Patients with Recurrent Pediatric Solid Tumors


Feb 17, 2022

KAHR and Cancer Focus Fund Announce First Patient Dosed in Phase 1b Clinical Trial of Anti-CD47 Product Candidate DSP107 in Blood Cancers USA - English USA - English


Feb 17, 2022

Immunicom Appoints Dr. Annette Marleau as Chief Technology Officer



Feb 17, 2022

Ribon Therapeutics, a Clinical Stage Biotechnology Company Targeting Stress Support Pathways in Cancer and Inflammation, Announces CEO Transition for Its Next Phase of Growth


Feb 17, 2022

KAHR and Cancer Focus Fund Announce First Patient Dosed in Phase 1b Clinical Trial of Anti-CD47 Product Candidate DSP107 in Blood Cancers


Feb 16, 2022

Electra Therapeutics Announces $84 Million Series B Financing and Unveils Its Novel SIRP‑Targeted Therapies for Immunological Diseases and Cancer


Feb 15, 2022

Grey Wolf Therapeutics Announces Formation of Clinical Advisory Board in Anticipation of Advancing First-in-Class Immuno-Oncology Approach into the Clinic


Feb 15, 2022

ZielBio Announces First Patient Dosed in Phase 1/2 Clinical Trial of ZB131, Its Novel Monoclonal Antibody Targeting Cancer Specific Plectin



Feb 15, 2022

Oxford Finance Announces the Closing of a $50 Million Credit Facility With OncoResponse


Feb 14, 2022

Vivacitas Oncology to Present at the 2022 BIO CEO and Investor Conference


Feb 14, 2022

OnQuality Pharmaceuticals to Present NOVA-II Phase 2 Trial Update and Oncologist Survey Demonstrating Oncodermatology Unmet Need at ASCO GU


Feb 10, 2022

Indapta Therapeutics Names Mark W. Frohlich, M.D., Chief Executive Officer and Raises Over $50 Million in Series A Financing and Commitments to Advance Development of G-NK Cell Therapy to Treat Multiple Types of Cancer


Feb 9, 2022

Cyclica launches Perturba Therapeutics, a spin out from the University of Toronto, creating the next-generation oncology biotech



Feb 8, 2022

Arrakis Therapeutics to Present at Guggenheim Healthcare Talks Oncology Conference


Feb 8, 2022

enGene Announces Positive Preliminary Phase 1/2 Data with EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer


Feb 8, 2022

SEngine Precision Medicine and Oncodesign Announce Collaboration Agreement for the Discovery of New Personalized Cancer Treatment for Aggressive and Untreatable Tumors


Feb 7, 2022

Actuate Therapeutics Announces Initiation of a Multicenter Randomized Trial of Elraglusib Plus FOLFIRINOX As First Line Therapy for Advanced Pancreatic Cancer


Feb 7, 2022

Endeavor BioMedicines Closes $101M Series B Financing to Advance Clinical-Stage Precision Medicine Pipeline



Feb 7, 2022

Treos Bio Announces First Patient Dosed in Phase 1b Trial of PolyPEPI1018 Immunotherapy for the Treatment of Metastatic Colorectal Cancer


Feb 3, 2022

Kriya Announces the Appointment of Ma’an Muhsin, M.D., as President and Chief Medical Officer of Its Oncology Therapeutic Area Division


Feb 2, 2022

Boundless Bio to Present at the Guggenheim Oncology Conference


Feb 2, 2022

Pimera Therapeutics Awarded Grant by US Department of Defense to Evaluate PMR-116, a Novel Inhibitor of RNA Polymerase I (Pol I) Transcription, in Patients with Prostate Cancer


Feb 1, 2022

Chemical Society Reviews Journal Explores How OncoTEX’s Gold-Based Compounds Can Activate the Immune System to Fight Cancer



Jan 31, 2022

Vivacitas Oncology Strengthens Its Neuro-Oncology Board With World-Class Advisor Dr. Katherine Peters, MD, PhD, FAAN


Jan 27, 2022

Oncolytics Biotech Partner Adlai Nortye Advances to the Second Dose Escalation Cohort of the Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment in Breast Cancer


Jan 27, 2022

EPIC SCIENCES AND BIOSPLICE THERAPEUTICS ANNOUNCE PARTNERSHIP FOR METASTATIC CANCER TRIALS


Jan 25, 2022

SNIPR BIOME Announces U.S Food and Drug Administration grants Fast Track Designation for SNIPR001 for Prevention of Bloodstream Infections in Hematologic Cancer Patients


Jan 24, 2022

ITM: Installation of New Isotope Production System at Bruce Power to Produce Medical Isotopes for Cancer Therapy Completed



Jan 20, 2022

Palleon Pharmaceuticals Announces IND Clearance for First-in-Class Cancer Immunotherapy Leveraging Glyco-Immunology


Jan 19, 2022

OnQuality Pharmaceuticals to Present Oncologist Survey Data Demonstrating Need for New Cancer Therapy-Associated Diarrhea Treatments at ASCO GI 2022


Jan 18, 2022

Rafael Pharmaceuticals Announces Ongoing Successful Enrollment and Opening of Additional Sites for Phase 2 Clinical Trial of CPI-613 (Devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer


Jan 18, 2022

Aktis Oncology Expands Leadership Team with Two Strategic Hires


Jan 18, 2022

Daiichi Sankyo to Divest Certain Cardiovascular and Other Legacy Products to Cosette Pharmaceuticals in the United States, Shifting Focus to Oncology Portfolio



Jan 18, 2022

Vivacitas Oncology to Present a Poster on AR-67 at the 3rd Annual Glioblastoma Drug Development Summit


Jan 17, 2022

Boundless Bio Appoints Peter Krein, Ph.D., as Vice President, Precision Medicine


Jan 13, 2022

Scorpion Therapeutics Enters Agreement with AstraZeneca to Discover, Develop and Commercialize Novel Cancer Treatments Against ‘Undruggable’ Targets


Jan 12, 2022

BioCurity Pharmaceuticals Inc. ('BioCurity' or ‘Company’) Announces Presentation of Data on Cerium Oxide Nanoparticles to Sensitize Radiation for Head and Neck Cancer at ACRO 2022 Summit


Jan 12, 2022

MiNK Therapeutics to Participate at Upcoming B. Riley Securities Virtual Oncology Conference



Jan 12, 2022

Nirogy Therapeutics Appoints Simon Pedder, Ph.D., as Chief Executive Officer


Jan 11, 2022

Biomica Announces Clearance for First-in-Human Phase I Study of BMC-128 in Combination with Bristol Myers Squibb's Anti-PD-1 Opdivo USA - English USA - English


Jan 11, 2022

ACELYRIN Appoints Melanie Gloria as Chief Operating Officer


Jan 11, 2022

Curebase and Persephone Biosciences Partner in Clinical Trial of Colorectal Cancer Among Diverse Populations


Jan 10, 2022

ArsenalBio Announces Expansion of Collaboration with Bristol Myers Squibb to Advance T Cell Therapy in Solid Tumors



Jan 10, 2022

Vivacitas Oncology to Present AR-67 at the Biotech Showcase Investor Conference


Jan 9, 2022

Laekna Therapeutics and Innovent Biologics obtain IND approval for combination therapy in patients with specific types of solid tumors who have been refractory to treatment with PD-1/PD-L1 inhibitors


Jan 7, 2022

Exscientia and Sanofi Establish Strategic Research Collaboration to Develop AI-driven Pipeline of Precision-Engineered Medicines


Jan 6, 2022

AKTIS ONCOLOGY TO PRESENT AT THE 40TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE


Jan 5, 2022

NiKang Therapeutics and AVEO Oncology Announce a Clinical Trial Collaboration and Supply Agreement to Evaluate the Combination of NKT2152, a HIF2α Inhibitor, and FOTIVDA (tivozanib) for the Treatment of Advanced Clear Cell Renal Cell Carcinoma



Jan 5, 2022

Elucida Oncology Provides Corporate Update and Outlines Key Upcoming Milestones


Jan 5, 2022

Elucida Oncology to Present at Two Upcoming Investor Conferences


Jan 4, 2022

OnQuality Pharmaceuticals Reports Topline Data from Phase 2 Trial of Treatment for Cancer Therapy Induced Skin Toxicity that Met Expectations


Jan 3, 2022

Vivacitas Oncology Welcomes Dr. Jai Grewal, MD, and Expands Its Neuro-Oncology Advisory Board


Dec 28, 2021

Therapeutic Solutions International Awarded Landmark Patent for Cancer and COVID-19 Treatment



Dec 27, 2021

VLP Therapeutics raises $21M Series A-1 for cancer treatment vaccine, infectious diseases vaccine RandD


Dec 24, 2021

Accutar Biotechnology Announces FDA Clearance of IND Application for Phase 1 Trial of AC0176 in Prostate Cancer


Dec 23, 2021

Aarvik Therapeutics and ArriVent Biopharma Announce Research Collaboration to Advance Novel Oncology Drug Candidate Using Aarvik’s Proprietary Modular Antibody Platform


Dec 22, 2021

Ligand’s Partner CStone Pharmaceuticals Receives Approval in China for Sugemalimab (Cejemly) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer in Combination with Chemotherapy


Dec 22, 2021

CSTONE ANNONCE L'APPROBATION D'UN NOUVEAU MÉDICAMENT EN CHINE, CEJEMLY (SUGEMALIMAB), QUI POURRAIT REMODELER LE PAYSAGE DE L'IMMUNO-ONCOLOGIE DANS LE CANCER DU POUMON France - Français USA - English USA - English Brazil - Português España - español Latin America - español



Dec 20, 2021

CG Oncology Announces First Patient Dosed in Japan in Phase 3 Monotherapy Study of CG0070 in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin


Dec 15, 2021

Elucida Oncology to Present Preclinical Data on ELU001 at the Antibody Engineering and Therapeutic Conference


Dec 15, 2021

Vivacitas Oncology Presents Its New Neuro-Oncology Advisor, Dr. Andrew Lassman MD, MS, FAAN


Dec 15, 2021

BridGene Biosciences Announces Research Collaboration with the Peter MacCallum Cancer Centre to Discover Targets and Small Molecule Drug Candidates for Ovarian Cancer


Dec 14, 2021

HiberCell to Collaborate with Merck on Phase 2 Clinical Trial of Odetiglucan in Combination with KEYTRUDA (pembrolizumab) in Patients with Metastatic Breast Cancer



Dec 13, 2021

Sermonix Pharmaceuticals Announces Poster Presentation at the 2021 San Antonio Breast Cancer Symposium


Dec 10, 2021

Technical Paper on AnPac Bio Novel CDA Cancer Detection Technology Published by Peer-Reviewed International Medical Journal


Dec 9, 2021

Carrick Therapeutics Presents Encouraging Clinical Data for Samuraciclib (CT7001) at the 2021 San Antonio Breast Cancer Symposium


Dec 9, 2021

iOnctura Presents Positive Clinical Data At ESMO-IO Supporting Advancement of IOA-289, a Novel Autotaxin Inhibitor, Into Phase Ib Pancreatic Cancer Studies


Dec 9, 2021

Denovo Biopharma and QIAGEN partner to develop companion diagnostic test for the treatment of Diffuse Large B-Cell Lymphoma (DLBCL)



Dec 9, 2021

Pyxis Oncology Appoints Martina Molsbergen as Interim Chief Business Officer


Dec 9, 2021

Sapience Therapeutics Announces Multiple Poster Presentations on ST101 at the 2021 San Antonio Breast Cancer Symposium


Dec 9, 2021

Inspirna Strengthens Scientific Advisory Board with Two Globally Renowned Experts in Gastrointestinal Oncology


Dec 9, 2021

Iterion Therapeutics Announces Initiation of Phase 1 Clinical Trial to Study Tegavivint in Combination with Osimertinib in Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer


Dec 7, 2021

HiberCell To Present New Data on Odetiglucan Plus Pembrolizumab in Ongoing Phase 2 Metastatic Breast Cancer Trial at San Antonio Breast Cancer Symposium



Dec 7, 2021

Immunicom Announces Promising Preliminary Data from its Immunopheresis Study in Late-Stage Cancer and Metastatic Melanoma Patients Presented at 2021 SITC Congress


Dec 7, 2021

Odyssey Therapeutics Announces $218 Million Series A Financing to Advance Next Generation Inflammation and Oncology Medicines


Dec 2, 2021

HUYABIO Announces the Exclusive License of the KRAS Inhibitor from Shanghai Jemincare Pharmaceutical


Dec 1, 2021

enGene Announces Poster Presentation at the Society of Urologic Oncology 2021 Annual Meeting


Dec 1, 2021

National University Cancer Institute, Singapore and MiNA Therapeutics Announce Initiation of a Phase 1 Clinical Study of MTL-CEBPA in Combination With First-line Standard of Care in Advanced Liver Cancer



Dec 1, 2021

Samus Therapeutics Announces Study Publication in Communications Biology on the Importance of Epichaperome Inhibition for Enhancing the Vulnerability of Cancer Cells


Dec 1, 2021

Curie Therapeutics Raises $75 Million Financing to Further its Mission of Transforming Cancer Care with Precision Radiopharmaceuticals


Dec 1, 2021

Accutar Biotechnology Announces First Patient Dosed with AC0682 in Phase 1 Study in Patients with ER-Positive / HER2-Negative Locally Advanced or Metastatic Breast Cancer


Nov 30, 2021

AFFPC Celebrates Giving Tuesday By Donating $200,000.00 To BERG's Project Survival


Nov 30, 2021

Vivacitas Oncology Announces Additions to Leadership Team and Board



Nov 30, 2021

Australian Biotech EnGeneIC Strikes Landmark Deal with Major US Biotech ImmunityBio for COVID-19 Vaccine and Cancer Treatment


Nov 29, 2021

Turnstone Biologics Announces Research Collaboration with Moffitt Cancer Center to Advance Novel TIL Immunotherapies for Solid Tumor Indications


Nov 29, 2021

Kineta Presents Phase 1/2 Clinical Trial Design of KVA12.1 at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting


Nov 29, 2021

Ranok Therapeutics Announces Agreement with Pfizer on Targeted Protein Degradation


Nov 29, 2021

Scorpion Therapeutics Reveals Highly-selective Lead Programs Targeting Mutant PI3Kα and EGFR Exon 20, Two Established Cancer Drivers with Broad Therapeutic Applicability



Nov 29, 2021

Ablaze Pharmaceuticals Launches with $75m Series A Financing to Bring Novel Targeted Radiopharmaceuticals to Treat Cancer Patients in the Greater China Market USA - English USA - español USA - Français USA - Deutsch


Nov 29, 2021

Ablaze Pharmaceuticals lance un financement de série A de 75 millions de dollars pour apporter de nouveaux produits radiopharmaceutiques ciblés afin de traiter les patients atteints de cancer sur le marché de la Grande Chine USA - Français USA - English USA - español USA - Deutsch


Nov 24, 2021

eFFECTOR Therapeutics Announces Publication of Zotatifin Preclinical Data in Frontiers in Oncology


Nov 22, 2021

Carrick Therapeutics to Present Clinical Data on Samuraciclib (CT7001), a First-In-Class Inhibitor of CDK7, at the 2021 San Antonio Breast Cancer Symposium


Nov 22, 2021

Elucida Oncology Appoints Ian Somaiya as Chief Financial Officer and Chief Business Officer



Nov 17, 2021

Eureka Therapeutics Announces Initiation of Phase I/II ARYA-2 Clinical Trial of ET140203 ARTEMIS T Cells to Treat Pediatric Liver Cancer


Nov 17, 2021

Regen BioPharma, Inc. Announces Signing of a Letter of Intent to Acquire an In vitro Diagnostics Start-Up Company Canary Oncoceutics, Inc. Which is Developing Functional Cancer Tests for Personalized Medicine


Nov 17, 2021

First Subject Dosed in Biosplice Therapeutics Phase 1b Clinical Trial in Oncology


Nov 16, 2021

NeoImmuneTech Presents Data in Three Posters at Society for Immunotherapy of Cancer Annual Meeting


Nov 16, 2021

Terumo Blood and Cell Technologies and Immunicom Establish Agreement to Launch Breakthrough Cancer Immunotherapy Treatment in Europe



Nov 16, 2021

Volastra Therapeutics Expands Leadership Team to Tackle Cancer


Nov 15, 2021

Phosplatin Therapeutics Collaborates with the National Cancer Institute For Phase 2 Proof of Concept Study of PT-112 in Thymoma and Thymic Carcinoma


Nov 15, 2021

CORRECTING and REPLACING Penrose TherapeuTx Appoints Pharmaceutical Leader David Sherris, Ph.D., as President and Chief Executive Officer


Nov 15, 2021

NKGen Biotech Announces Positive SNK01 Clinical Trial Results Presented at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting


Nov 15, 2021

T-knife Therapeutics Reports Preclinical Efficacy Data Induced by TK-8001, a Novel MAGE-A1-Specific TCR-T



Nov 13, 2021

CG Oncology Presents Preliminary Phase 2 Data with CG0070 in Combination with KEYTRUDA (pembrolizumab) in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin


Nov 12, 2021

MiNA Therapeutics Highlights Clinical Data Supporting the Further Development of MTL-CEBPA as an Anti-cancer Immunotherapy


Nov 12, 2021

Grey Wolf Therapeutics Presents Promising Preclinical Data on First-in-Class ERAP1 Inhibitors at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)


Nov 12, 2021

Bicara Therapeutics Presents Promising New Preclinical Data for Lead Immunotherapy Program BCA101 at the Society for Immunotherapy of Cancer 2021 Annual Meeting


Nov 12, 2021

Elicio Therapeutics Presents Preclinical Data on AMP TCR-T and CAR-T Combination Therapies at the 2021 Society for Immunotherapy of Cancer Annual Meeting



Nov 12, 2021

Apexigen Announces New Phase 2 Clinical Data on CD40 Antibody Sotigalimab at the SITC 2021 Annual Meeting


Nov 11, 2021

Prokarium Shares Preclinical Proof-of-Concept Data on Its Microbial Immunotherapy Bladder Cancer Program at SITC 2021


Nov 10, 2021

Pyxis Oncology to Present at the Jefferies London Healthcare Conference


Nov 10, 2021

Nouscom to present interim data from Phase 1 trial evaluating NOUS-209, an 'off-the-shelf' neoantigen cancer vaccine for the treatment of MSI-H solid tumors


Nov 10, 2021

Hummingbird Bioscience Announces Trials in Progress Poster Presentation at the Society for Immunotherapy of Cancer 2021 36th Annual Meeting



Nov 9, 2021

HUYABIO Announces the Exclusive License of the Wee1 Inhibitor from Shanghai Pharmaceuticals


Nov 9, 2021

HotSpot Therapeutics to Present New Data Indicating Successful Targeting of CBL-B at 2021 Society for Immunotherapy of Cancer Annual Meeting


Nov 9, 2021

Immune-Onc Therapeutics to Present Data Supporting Therapeutic Potential of LAIR1 Antagonist Antibodies at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting


Nov 9, 2021

Dragonfly Therapeutics Announces DF1001 Granted Orphan Drug Designation in the US for Esophageal Cancer


Nov 9, 2021

Istari Oncology Presents Data on Its PVSRIPO Immunotherapy at the Annual November Meetings for the Society for Immunology of Cancer (SITC) and the Society for Neuro-Oncology (SNO)



Nov 9, 2021

MAIA Biotechnology, Inc. Announces Poster Presentation at the Society for Immunotherapy of Cancer 36th Annual Meeting (SITC)


Nov 9, 2021

Codagenix to Present Promising Preclinical Data for Oncolytic Virus Therapeutic CodaLytic™ at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting


Nov 8, 2021

NeoImmuneTech Announces First Patient Dosed in Phase 2 Study of NT-I7 (efineptakin alfa) in Combination with PD-L1 Checkpoint Inhibitor in Frontline Locally Advanced or Metastatic Non-Small Cell Lung Cancer


Nov 8, 2021

Marengo Therapeutics Launches with $80M from ATP, Appoints CEO Zhen Su, MD, to Deliver Breakthrough Cancer Treatments Using Its Selective T Cell Activation Repertoire (STAR) Platform


Nov 4, 2021

Enterome - Significant Progress with OncoMimics™ and EndoMimics™ pipelines of transformational medicines for cancer and immune diseases



Nov 4, 2021

Shasqi to Present Data Updates at Upcoming SITC and CTOS Meetings


Nov 4, 2021

Inspirna Announces Clinical Collaboration with Bristol Myers Squibb to Study RGX-104 in Combination with Yervoy (ipilimumab) for Treatment of Metastatic Endometrial Cancer


Nov 3, 2021

Integral Molecular Enters into Antibody License Agreement with AstraZeneca for Oncology Therapeutics


Nov 3, 2021

Intensity Therapeutics' Data on Lead Asset, INT230-6, Accepted for Presentation at Two Major Scientific Clinical Oncology Conferences in November


Nov 3, 2021

Gold Technology for Immune Response Cancer Therapy Licensed to OncoTEX



Nov 2, 2021

Immunicom Conference Highlights Innovation in Clinical Trial Design to Advance its Breakthrough Cancer Immunotherapy Platform


Nov 2, 2021

Prokarium Promotes Livija Deban to Chief Scientific Officer to Drive Pipeline Expansion in Cancer Immunotherapy


Nov 2, 2021

OncoResponse Announces Initiation of Phase 1 Trial of OR2805 - Human Monoclonal Antibody Derived from Elite Responder to Cancer Immunotherapy - in Patients with Advanced Cancer


Oct 29, 2021

Sapience Therapeutics Announces Multiple Poster Presentations on ST101 at 28th Prostate Cancer Foundation Annual Scientific Retreat and 18th International Congress of the Society for Melanoma Research


Oct 28, 2021

Rafael Holdings Provides Update on Rafael Pharmaceuticals’ Two Phase 3 Trials of CPI-613 (Devimistat), AVENGER 500 in Metastatic Pancreatic Cancer and ARMADA 2000 in Relapsed or Refractory Acute Myeloid Leukemia



Oct 28, 2021

Rafael Pharmaceuticals Provides Update on Pivotal Phase 3 Clinical Trial in Patients with Metastatic Pancreatic Cancer and Interim Analysis of Pivotal Phase 3 Clinical Trial in Patients with Relapsed or Refractory Acute Myeloid Leukemia


Oct 28, 2021

Ensoma Strengthens Scientific Advisory Board with Leaders in Oncology and Primary Immune Deficiencies


Oct 27, 2021

Inceptor Bio Announces Agreement to Acquire Gainesville, FL GMP Facility And Transfer Operating Team From Arranta Bio To Accelerate Cell Therapies To Cure Cancer


Oct 27, 2021

XtalPi and Signet Expand AI Drug Discovery Collaboration to Novel Cancer Target


Oct 26, 2021

HiberCell and Strasbourg Institute for Precision Medicine Publish Machine Learning Data and Approach on Causal Biology of Severe COVID-19



Oct 26, 2021

Diverse Biotech Announces Its DBT-12733 Molecule Demonstrated to Be Up to 8,000 Times More Effective Than Temozolomide for Brain Cancer


Oct 25, 2021

Flare Therapeutics Appoints Daphne Karydas as COO and CFO, and Michaela Bowden, PhD, as SVP of Biology and Translation


Oct 25, 2021

Hummingbird Bioscience to Collaborate with Merck on Clinical Trial of Anti-VISTA Antibody HMBD-002 in Combination with KEYTRUDA (Pembrolizumab) for Treatment of Cancer


Oct 25, 2021

AnHeart Therapeutics Announces First Patient Dosed in Global Phase 2 TRUST-II Study for Taletrectinib in ROS1 Fusion-Positive Lung Cancer


Oct 23, 2021

OncXerna Therapeutics Announces New Biomarker Data from Retrospective Analysis of Results from Phase 1b Ovarian Cancer Trial of Navicixizumab Plus Paclitaxel at the ESGO 2021 Congress



Oct 21, 2021

Rakuten Medical and Karkinos Healthcare Announce Strategic Partnership to Expand the Reach of Novel Cancer Care in India


Oct 21, 2021

Cedilla Therapeutics Unveils Lead Programs for the Conditional Inhibition of TEAD and CDK2, Two High Value and Historically Undruggable Cancer Drivers


Oct 21, 2021

Mablink Bioscience and Emergence Therapeutics Enter Into a Licensing Agreement to Develop Antibody Drug Conjugate as a Potential Cancer Therapy


Oct 20, 2021

NKGen Biotech Announces Acceptance of SNK01 Abstract for Presentation at the 2021 Connective Tissue Oncology Society Annual Meeting


Oct 20, 2021

Crescendo Biologics Announces Prestigious New Collaboration With the Institute of Cancer Research, London



Oct 20, 2021

ImCheck Publishes Comprehensive Overview of the Development Results of Its First-in-class Cancer Immunotherapeutic Targeting BTN3A to Activate Vγ9Vδ2 T Cells in Science Translational Medicine


Oct 19, 2021

ITM and Clovis Oncology Announce Lutetium-177 Clinical Supply Agreement


Oct 18, 2021

Ipsen Adds Another Program Into Its Pre-Clinical RandD Oncology Pipeline Through an Exclusive Worldwide Collaboration With Accent Therapeutics, Targeting the RNA Modifying Protein, METTL3


Oct 14, 2021

Oncolytics BiotechPartner Adlai Nortye Doses First Patient in Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment in Breast Cancer


Oct 13, 2021

Rhizen Pharmaceuticals AG Announces First Patient Dosing in a Phase II Study of Tenalisib (RP6530) in Locally Advanced or Metastatic Breast Cancer Patients



Oct 12, 2021

First Patient Dosed With PVSRIPO in Istari Oncology’s LUMINOS-103 Phase 1/2 Bladder Cancer Sub-Study


Oct 12, 2021

Sapience Therapeutics Awarded SBIR Grant from National Cancer Institute (NCI) of the National Institutes of Health (NIH) for ST316, its β-catenin antagonist peptide (BCAP) Program


Oct 12, 2021

CG Oncology to Present Two Programs at The Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting


Oct 12, 2021

AUM Biosciences announces closing of USD $27Million in a "Series A" Round of funding to advance its clinical stage pipeline of precision and targeted cancer therapies


Oct 11, 2021

CatalYm Presents Updated Tolerability and Preliminary Pharmacodynamics Data from GDF-15 Targeting First-in-Human Clinical Trial in Plenary Session at AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics



Oct 7, 2021

LIPAC Oncology Secures Broad Patent Protection for Proliposomal Paclitaxel Compositions Formulated for Delivery to the Bladder and Ureter for the Treatment of Solid Tumor Carcinomas


Oct 7, 2021

Baylor College of Medicine Presents eFFECTOR Therapeutics-Backed Preclinical Data Supporting Development of Zotatifin in Triple-Negative Breast Cancer at 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics


Oct 7, 2021

Second Genome Presents Preclinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Demonstrating that a Novel Peptide, SG-3-0020, Upregulates Co-stimulatory and Checkpoint Pathways


Oct 7, 2021

Boundless Bio Presents Data on Extrachromosomal DNA (ecDNA) Driven Resistance to KRASG12C Inhibitors at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics 2021


Oct 7, 2021

Immunicom Hires Former FDA Clinician and Medical Device Reviewer to Rapidly Progress Launch of Novel Cancer Immunotherapy



Oct 7, 2021

BridGene Biosciences' IMTAC ™ Small Molecule Discovery Platform Featured in Multiple Presentations at 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics


Oct 7, 2021

Amunix Presents Preclinical Data on Its XPAT T Cell Engager Platform at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics


Oct 6, 2021

Apexigen Announces First Patient Dosed in Phase 3 Pivotal Trial for BD0801, an Anti-VEGF Monoclonal Antibody, in Combination Therapy for Ovarian Cancer


Oct 6, 2021

PanTher Therapeutics Doses First Two Patients in Phase 1 Trial of PTM-101 for Treatment of Pancreatic Cancer


Oct 6, 2021

Step Pharma Appoints Experienced Cancer Drug Developer Adrian Senderowicz to Board of Directors



Oct 5, 2021

Lutris Pharma Initiates Part Two of its Phase 1/2 Trial of LUT014 To Treat Radiation Dermatitis in Breast Cancer Patients USA - English USA - English USA - English


Oct 5, 2021

Aulos Bioscience to Present New Preclinical Data on Computationally Evolved IL-2 Human Antibody AU-007 at 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting


Oct 5, 2021

Lutris Pharma Initiates Part Two of its Phase 1/2 Trial of LUT014 To Treat Radiation Dermatitis in Breast Cancer Patients USA - English Israel - English


Oct 4, 2021

NeoImmuneTech to Present Three Posters at Society for Immunotherapy of Cancer Annual Meeting


Oct 1, 2021

Compass Therapeutics and ABL Bio Announce Presentation of CTX-009 Clinical Data as a Plenary Session of the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics



Oct 1, 2021

T-knife Therapeutics Announces Upcoming Presentations at Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting


Oct 1, 2021

Vigeo Therapeutics to Present New Phase 1/2 VT1021 Data from its Pancreatic Cancer Expansion Study at the Society for Immunotherapy of Cancer's 2021 Annual Meeting


Oct 1, 2021

Aleta Biotherapeutics to Present at Society for Immunotherapy of Cancer


Sep 30, 2021

Baylor College of Medicine to Present eFFECTOR Therapeutics-Supported Research at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics


Sep 30, 2021

Gennao Bio Announces Abstract Accepted for Poster Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics



Sep 30, 2021

OncoNano Medicine to Present at The American Association for Cancer Research Virtual Conference on Tumor Immunology and Immunotherapy


Sep 30, 2021

BridGene Biosciences Announces Titles and Authors of Five Abstracts Accepted for Poster Presentations at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics


Sep 30, 2021

CatalYm To Present Update From GDF-15 Targeting First-in-Human I/O Clinical Trial in Plenary Session at AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics


Sep 30, 2021

Edison Oncology and Apollomics Inc. Announce Treatment of First Patient For EO1001 (APL-122) in a Phase I/IIa Clinical Trial


Sep 28, 2021

Kineta Announces Poster Presentation at the 2021 American Association for Cancer Research Conference on Tumor Immunology and Immunotherapy



Sep 28, 2021

Immunicom’s Alternative Subtractive Cancer Therapy Recognized with Zoom’s Healthcare Innovation Award


Sep 28, 2021

Cybrexa Therapeutics to Present at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics


Sep 26, 2021

JW Therapeutics Announces Updated 1-year Follow-up Result of Relmacabtagene Autoleucel Injection At the 24th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO)


Sep 22, 2021

Boundless Bio Announces Upcoming Presentation at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics 2021


Sep 22, 2021

Hexagon Bio Raises $61 Million to Advance Novel Small-Molecule Medicines Mined from Microbial Genomes



Sep 22, 2021

CG Oncology and Roche to Collaborate on Clinical Trial of Oncolytic Immunotherapy CG0070 as Part of Novel Combination for Various Solid Tumor Indications


Sep 22, 2021

OncoNano Medicine Announces Expanded Research Collaboration With UT Southwestern Medical Center to Advance Development of New Cancer Therapies


Sep 21, 2021

Vigeo Therapeutics Provides Clinical Update for Lead Asset VT1021 and Welcomes New Chief Executive Officer


Sep 21, 2021

LIPAC Oncology to Present at Upcoming Investor Conferences


Sep 21, 2021

Immunicom Introduces 2nd Product of Immunopheresis Therapy Platform Designed to Suppress Cancer Progression and Overcome Therapeutic Resistance



Sep 21, 2021

858 Therapeutics Launches with Proven Team and $60 Million Series A Financing


Sep 21, 2021

Zenith Epigenetics and Newsoara Announce Initiation of a Randomized Phase 2b Metastatic Castration-Resistant Prostate Cancer (mCRPC) Study


Sep 21, 2021

Seneca Therapeutics, Inc. Announces Launch of a Novel Cancer Gene Delivery Platform based on SVV-001 Technology


Sep 21, 2021

Accutar Biotechnology Announces FDA Clearance of IND Application for Phase 1 Trial of AC0682 in ER-Positive Breast Cancer


Sep 21, 2021

Boehringer Ingelheim Acquires Abexxa Biologics to Further Expand its Research Efforts in Cancer Immunology and Novel Immunotherapeutic Approaches



Sep 20, 2021

Fore Biotherapeutics Continues to Build Leadership Team with Executive and Board Appointments


Sep 19, 2021

Appealing Data of CARsgen Therapeutics' CAR-T (CT041) in Advanced Gastric Cancer Presented at ESMO


Sep 17, 2021

Elucida Oncology Announces First Patient Dosed in Phase 1/2 Study of ELU001 in Patients with Advanced, Recurrent, or Refractory Cancers Overexpressing Folate-Receptor Alpha (FRα)


Sep 16, 2021

BERG to Present Latest Research to Improve Pancreatic Treatment at The European Society for Medical Oncology (ESMO) 2021 Congress


Sep 16, 2021

Nouscom announces initial results from Phase 1 trial for NOUS-209, an 'off-the-shelf' neoantigen cancer vaccine, in MSI-H solid tumors



Sep 16, 2021

Carrick Therapeutics Presents Encouraging Initial Efficacy for Samuraciclib (CT-7001) in Combination with Fulvestrant in Advanced HR+, HER2- Breast Cancer Patients at ESMO Congress 2021


Sep 16, 2021

OncXerna Therapeutics Announces New Phase 2 and Biomarker Data in Gastric Cancer from Bavituximab Program at the ESMO Congress 2021


Sep 16, 2021

Laekna Therapeutics reported positive results in two clinical studies for the treatment of various stages of prostate cancer at the ESMO Congress


Sep 16, 2021

Endeavor BioMedicines Licenses ULK1/2 Inhibitor Program from Salk Institute and Sanford Burnham Prebys to Broaden Its Precision Oncology Pipeline


Sep 16, 2021

Shasqi Presents Initial Data Validating Approach of Click Chemistry Activated Oncology Therapeutics at ESMO Congress 2021



Sep 14, 2021

Pyxis Oncology Appoints Jay M. Feingold, M.D., Ph.D., as Chief Medical Officer


Sep 14, 2021

Immunicom Presents Promising Preliminary Data from Immunopheresis Studies in Late-Stage Cancer Patients at JCA-AACR 2021


Sep 14, 2021

ROME Therapeutics Secures $77 Million in Series B Financing to Advance Repeatome-derived Pipeline for Cancer and Autoimmune Diseases and Expand Repeatomics Platform


Sep 13, 2021

Sapience Therapeutics Announces Poster Presentation on ST101 at the European Society for Medical Oncology (ESMO) Congress 2021


Sep 13, 2021

ITM and Chengdu Gaotong Isotope Co. Ltd. Form Joint Venture to Expand Access to ITM’s Diagnostic and Therapeutic Radioisotopes in China



Sep 9, 2021

USPTO Grants ONK Therapeutics’ Foundational Patent for CISH Knockout in NK Cells for Use in Cancer Therapies


Sep 9, 2021

Flamingo Therapeutics Expands Alliance with Ionis Pharmaceuticals to Develop RNA-targeted Therapies for Oncology


Sep 9, 2021

CG Oncology Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Oncolytic Immunotherapy CG0070 in Combination with OPDIVO (nivolumab) in Metastatic Urothelial Cancer


Sep 9, 2021

PharmAbcine Announces Joint Patent Application with MSD for the Treatment of Cancer


Sep 8, 2021

Jasper Therapeutics Initiates New Clinical Trial with National Cancer Institute to Evaluate JSP191 in GATA2-related Myelodysplastic Syndromes



Sep 8, 2021

Pyxis Oncology Strengthens Board of Directors


Sep 7, 2021

Istari Oncology to Participate in Upcoming Virtual Investor Conferences


Sep 7, 2021

Systems Oncology to Present at Upcoming Scientific and Investor Conferences


Sep 2, 2021

KAHR Announces FDA Clearance of IND Application for Phase 1b Trial of its Lead Anti-CD47 Candidate in Blood Cancers USA - English USA - English


Sep 2, 2021

KAHR Announces FDA Clearance of IND Application for Phase 1b Trial of its Lead Anti-CD47 Candidate in Blood Cancers



Sep 1, 2021

OncoQuest Pharmaceuticals Inc. Announces First Patient Enrolled in Each of Two Investigator Initiated Clinical Trials of Oregovomab in Combination Therapy for the Treatment of Recurrent Ovarian Cancer


Sep 1, 2021

Innovative Cellular Therapeutics Receives FDA Clearance of IND Application to Initiate a Phase 1 Clinical Trial for GCC19CART, a CoupledCAR Platform Product Candidate for Relapsed or Refractory Metastatic Colorectal Cancer


Aug 31, 2021

Pyxis Oncology Appoints Pamela Yanchik Connealy as Chief Financial Officer


Aug 31, 2021

Immunicom Hires World-Renowned Oncologist to Rapidly Progress Launch of Non-Pharmaceutical Cancer Therapy


Aug 30, 2021

Umoja Biopharma Breaks Ground on Extensive Manufacturing Facility for its Next-Generation CAR T Immunotherapies



Aug 26, 2021

Innovent and Bolt Biotherapeutics Announce Collaboration to Develop Three New Oncology Boltbody™ ISAC Programs


Aug 26, 2021

Laekna Therapeutics Receives IND Approvals in China and US for Phase Ib/III Global Multi-center Clinical Study of Afuresertib in combination with fulvestrant for patients with HR+/HER2- breast cancer


Aug 25, 2021

eFFECTOR Therapeutics Debuts as Publicly Traded Next-Generation Oncology Company Advancing Mature Pipeline with New Class of Cancer Therapies


Aug 25, 2021

BridgeBio Pharma and LianBio Announce First Patient Treated in Phase 2a Trial of Infigratinib in Patients with Gastric Cancer and Other Advanced Solid Tumors


Aug 25, 2021

Rafael Pharmaceuticals Announces the Successful Completion of Phase 1b Clinical Trial and Initiates Phase 2 for CPI-613 (devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer



Aug 24, 2021

Locust Walk Acquisition Corp.’s Stockholders Approve Business Combination with eFFECTOR Therapeutics to Create Next-Generation Oncology Company Developing New Class of Cancer Therapies


Aug 24, 2021

Nouscom announces first patient dosed in a Phase 1b Trial with NOUS-PEV, a novel personalized cancer immunotherapy, in advanced melanoma or lung cancer


Aug 20, 2021

Dialectic Therapeutics Receives $14.4 Million Texas Company Product Development Research Award from the Cancer Prevention and Research Institute of Texas


Aug 18, 2021

Treos Bio Announces FDA Clearance of IND Application for PolyPEPI1018 Immunotherapy for the Treatment of Metastatic Colorectal Cancer


Aug 18, 2021

Ranok Therapeutics Secures $40 Million Series B Financing to Advance its Innovative Targeted Protein Degradation Pipeline



Aug 17, 2021

Carrick Therapeutics to Present First Clinical Data on Samuraciclib (CT-7001), a First-In-Class Inhibitor of CDK7 at the European Society for Medical Oncology (ESMO) Congress 2021


Aug 17, 2021

Istari Oncology Initiates Its Phase I/II Sub-Study Evaluating PVSRIPO in Patients with Head and Neck Cancer


Aug 17, 2021

Zenith Epigenetics Announces a Publication in the Journal of Cancer Gene Therapy with Compelling Data for the Treatment of ER-Positive Breast Cancer Patients


Aug 16, 2021

HiberCell Expands Translational Oncology Toolbox by Acquiring Genuity Science, Inc.


Aug 16, 2021

Exelixis and Invenra Expand Collaboration to Discover and Develop Novel Biologics in Oncology



Aug 16, 2021

Carrick Therapeutics Receives FDA Fast Track Designations for Two Samuraciclib Combinations for the Treatment of HR+, HER2ꟷ Advanced Breast Cancer and Locally Advanced or Metastatic Triple Negative Breast Cancer


Aug 16, 2021

Immunicom Continues Successful Immunopheresis Clinical Trial in Advanced, Non-Small Cell Lung Cancer Treatment with Acibadem University


Aug 16, 2021

Carrick Therapeutics Receives FDA Fast Track Designations for Two Samuraciclib Combinations for the Treatment of HR+, HER2- Advanced Breast Cancer and Locally Advanced or Metastatic Triple Negative Breast Cancer


Aug 16, 2021

Carrick Therapeutics Receives FDA Fast Track Designations for Two Samuraciclib Combinations for the Treatment of HR+, HER2 Advanced Breast Cancer and Locally Advanced or Metastatic Triple Negative Breast Cancer


Aug 15, 2021

InxMed's IN10018 Receives U.S. FDA Fast Track Designation for the Treatment of Platinum-resistant Ovarian Cancer



Aug 11, 2021

BridGene Biosciences Announces Acceptance of Five Abstracts for Poster Presentations at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics


Aug 10, 2021

Nouscom highlights innovative science behind VENUS, its novel algorithm for identifying and prioritizing patient-specific tumor neoantigens for personalized cancer immunotherapy


Aug 10, 2021

Tango Therapeutics Debuts as Publicly Traded Precision Oncology Company Focused on the Next Generation of Targeted Cancer Therapies


Aug 5, 2021

Versant Ventures Announces Acquisition of Portfolio Company Vividion Therapeutics


Aug 4, 2021

eFFECTOR Therapeutics Initiates Phase 2a Expansion Cohorts Evaluating Zotatifin in Breast Cancer and KRAS-mutant Non-small Cell Lung Cancer



Aug 4, 2021

Strand Therapeutics Awarded Two Phase I NIH SBIR Grants to Advance Programmable, Long-Lasting mRNA Therapeutics for Melanoma and Breast Cancer


Aug 3, 2021

Lutris Pharma Doses First U.S. Patients in Phase 2 Trial of LUT014 -- a Topical Gel for the Reduction of Dose-Limiting Acneiform Lesions -- in Metastatic Colorectal Cancer Patients Treated with EGFR Inhibitor Therapy USA - English USA - English USA - English


Aug 3, 2021

Tachyon and AbCellera Collaborate to Develop Novel Antibody Therapeutic Targeting TGF-β Superfamily Member for the Treatment of Cancer


Aug 2, 2021

Carrick Therapeutics Announces Collaboration with Roche to Evaluate Novel Samuraciclib Combination to Treat HR+ Breast Cancer


Aug 2, 2021

DSS Continues to Grow its Healthcare Segment through $1M Investment in Vivacitas Oncology



Jul 29, 2021

Prokarium Appoints Uz Stammberger as Chief Medical Officer to Drive Clinical Development in Oncology


Jul 29, 2021

BERG Reveals New Study That Will Seek to Enhance Diagnosis and Treatment of Prostate Cancer


Jul 28, 2021

Bridge Medicines Enters Exclusive License Agreement with Cornell University for UBR5 Inhibitor Program to Treat Resistant Cancers


Jul 27, 2021

Amgen To Acquire Privately Held Teneobio For $900 Million In Cash With Future Contingent Milestone Payments


Jul 22, 2021

Ribon Therapeutics Announces Publication in Cancer Cell of Pre-Clinical and Mechanism of Action Data for RBN-2397



Jul 21, 2021

Eureka Therapeutics Announces Initiation of Phase I/II ARYA-3 Clinical Trial of GPC3 Targeting ARTEMIS T Cell Therapy in Liver Cancer


Jul 21, 2021

Exscientia and GT Apeiron Therapeutics Enter Oncology Joint Venture


Jul 20, 2021

CureLab Oncology Granted US Patent for Therapeutic Use of its Lead Product in ALS, Alzheimer's, Huntington's, and Parkinson's Diseases


Jul 20, 2021

Immunicom’s Data at ASCO Expand on the Antitumor Activity of its Novel Non-Pharmaceutical Immunotherapy in Late-Stage Breast Cancer Patients


Jul 19, 2021

Elucida Oncology Submits IND Application for ELU-001 for the Treatment of Cancers Overexpressing Folate-Receptor Alpha



Jul 19, 2021

Frontier Medicines Raises $88.5 Million Series B Financing to Advance Precision Oncology and Targeted Protein Degradation Pipeline


Jul 14, 2021

Iterion Therapeutics Hires Jean Chang as Chief Operating Officer


Jul 14, 2021

GigaGen Publishes Research Describing Novel Mechanism of Action and Therapeutic Potential of its anti-CTLA-4 Drug Candidate, GIGA-564


Jul 12, 2021

Enterome announces first patient dosed in a Phase 1/2 trial with second OncoMimics™ vaccine, EO2463, in non-Hodgkin lymphoma


Jul 7, 2021

Treos Bio Enters into Clinical Collaboration to Evaluate its Polypeptide Cancer Immunotherapy PolyPEPI1018 in Combination with Roche’s PD-L1-Inhibitor



Jul 6, 2021

Sitryx licenses intellectual property rights for inhibitors of a new target in immunometabolism from Cancer Research UK in exclusive worldwide agreement


Jul 2, 2021

Transcenta Provides Program Update for Anti-Claudin18.2 Monoclonal Antibody TST001 and Reports Promising Early Anti-Tumor Responses in Patients with Gastric Cancer


Jun 30, 2021

Sirnaomics Doses First Patient in Phase 2b Study of STP705 for Treatment of Squamous Cell Skin Cancer


Jun 30, 2021

ArriVent Biopharma Launches with Up To $150M in Series A Financing and Strategic Licensing Agreement for Clinical-Stage Oncology Asset


Jun 29, 2021

Applied BioMath, LLC Announces Collaboration with Ichnos Sciences for Systems Pharmacology Modeling for a Bispecific Antibody in Oncology



Jun 29, 2021

FDA Grants Rafael Pharmaceuticals Orphan Drug Designation for CPI-613 (Devimistat) for Treatment of Biliary Cancer


Jun 29, 2021

IONTAS Collaboration With F-star Enters Oncology Phase 1 Clinical Trial


Jun 29, 2021

Ixaka and SomaLogic Enter Research Collaboration to Develop Bispecific Agents for Oncology


Jun 25, 2021

Research showed that InxMed FAK Inhibitor (IN10018) Overcomes Drug Resistance of KRAS G12C inhibitors and Synergizes with KRAS G12C inhibitors in Treating Cancer


Jun 24, 2021

Anavo Therapeutics Strengthens Scientific Advisory Board with Industry-Leading Drug Discovery Experts in Oncology



Jun 24, 2021

Elevation Oncology Announces Pricing of Initial Public Offering


Jun 24, 2021

Vividion Therapeutics Earns First Milestone Payment for Advancement of Program Addressing High Value Oncology Target


Jun 24, 2021

Sirnaomics Doses First Patient in Phase 1 U.S. Clinical Study of STP705 for Treatment of Liver Cancer


Jun 24, 2021

Kineta's Thierry Guillaudeux Participated on Multiple Panel Presentations During Virtual Symposium on VISTA: A New Immunotherapy Approach to Treating Cancer


Jun 24, 2021

Zenith Epigenetics Announces a Publication Highlighting the Role of ZEN-3694 in Overcoming Resistance to Therapies in Metastatic Castration-Resistant Prostate Cancer



Jun 23, 2021

Aleta Biotherapeutics and Cancer Research UK Collaborate to Advance Blood Cancer Therapy Into the Clinic


Jun 23, 2021

Immunicom Presentation Defines Breakthrough Subtractive Therapy’s Role in “New Era” Cancer Care at LSI’s Annual Emerging MedTech Summit


Jun 23, 2021

Orum Therapeutics Closes $84 Million Series B Financing to Advance Novel Targeted Protein Degrader Payloads into Clinical Trials for Cancer


Jun 22, 2021

vTv Therapeutics and Cantex Pharmaceuticals Announce Strategic Licensing Agreement for Development and Commercialization of Azeliragon for Treatment of Cancer


Jun 22, 2021

TRexBio Closes the Final Tranche of $59 Million Series A Financing to Advance Innovation in Tissue Immunobiology for the treatment of Cancer and Inflammatory Diseases



Jun 21, 2021

Rafael Holdings Announces Strategic Merger with Rafael Pharmaceuticals to Form a Focused Late-Stage Clinical Oncology Company


Jun 20, 2021

Prestige Biopharma’s First-in-Class Pancreatic Cancer Treatment, PBP1510, Receives Approval for Clinical Trial in France


Jun 17, 2021

Aura Biosciences Assembles New Bladder Cancer Focused Scientific Advisory Board


Jun 17, 2021

Cullgen Announces Prominent Publication by Cullgen Co-Founders Jian Jin and Yue Xiong in Nature Reviews Cancer


Jun 17, 2021

Elevation Oncology Announces Appointment of Joseph Ferra as Chief Financial Officer



Jun 17, 2021

PanTher Therapeutics Closes Oversubscribed $5.4M Series A Round, Expands Board of Directors, As Company Prepares to Initiate First Clinical Trial of Novel Localized Treatment of Pancreatic Cancer


Jun 16, 2021

Apexigen and the Nordic Society of Gynaecological Oncology – Clinical Trial Unit Announce Collaborative Phase 2 Study of Sotigalimab (APX005M) in Combination Therapy for Ovarian Cancer


Jun 15, 2021

Caris Life Sciences and Elevation Oncology Announce Joint Discovery and Development Collaboration Focused on Oncogenic Fusions and Driver Mutations


Jun 15, 2021

RayzeBio Secures $108 Million Series C Financing to Drive Forward Its Pipeline of Targeted Radiopharmaceuticals for Cancer


Jun 15, 2021

OncoMyx Announces Exclusive Option to License Intellectual Property Rights for Myxoma Virus Technology from University of Florida



Jun 15, 2021

Linnaeus Therapeutics Announces Expanded Clinical Collaboration with Merck to Include Multiple Additional Cohorts to Evaluate LNS8801 in Combination with KEYTRUDA in Patients with Advanced Cancer


Jun 14, 2021

Istari Oncology Announces FDA Granted Fast Track Designation to PVSRIPO for the Treatment of Advanced Melanoma


Jun 14, 2021

Asher Bio Appoints Leading Experts in Immunology, Oncology and Protein Therapeutics to its Scientific Advisory Board


Jun 10, 2021

Immunicom Presents Promising Clinical Trial Data at AACR in Late-Stage Breast Cancer Patients Treated with Novel Non-Pharmaceutical Immunotherapy


Jun 10, 2021

ITM Announces EUR 25 Million (USD 30 M) Private Equity Financing to Support Advancement of Proprietary Precision Oncology Pipeline



Jun 9, 2021

LIPAC Oncology Announces Two-Year Recurrence Free Survival Data for Phase 1/2a Study of LiPax in Patients With Non-Muscle Invasive Bladder Cancer


Jun 8, 2021

ONK Therapeutics and Trinity College Dublin Collaborate in an Enterprise Ireland Funded Project to Optimize Metabolism of NK Cells for Improved Cancer Therapies


Jun 8, 2021

Cybrexa Therapeutics Announces Publication of Peer-Reviewed Article in NAR Cancer


Jun 8, 2021

Istari Oncology Hires Jamie Iudica as Chief Manufacturing Officer Expanding the Company’s Growing Executive Team


Jun 8, 2021

Pyxis Oncology Strengthens Leadership Team with Executive and Scientific Advisory Board Appointments



Jun 7, 2021

NeoImmuneTech Trial Data Presented at American Society of Clinical Oncology Annual Meeting


Jun 4, 2021

Biosight Presents Updated Clinical Data from Ongoing Phase 2b Study of Aspacytarabine (BST-236) in an Oral Presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting


Jun 4, 2021

Candel Therapeutics Announces Data from Phase 1 Trial of CAN-3110 in Recurrent High-Grade Glioma at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting


Jun 4, 2021

Tarveda Therapeutics Presents Promising Phase 2 Data of PEN-221 in Gastrointestinal Mid-gut Neuroendocrine Tumors


Jun 3, 2021

Geneos Therapeutics Announces Clinical Updates on Personalized Cancer Vaccine Program



Jun 2, 2021

BERG to Present Phase 1 Results of BPM 31510-IV and Identifies Therapeutic Opportunities for Recurrent GBM Patients at 2021 American Society of Clinical Oncology (ASCO) Meeting


Jun 2, 2021

Intensity Therapeutics’ INT230-6 Demonstrates Efficacy as Either Monotherapy or in Combination with Checkpoint Inhibitors in Patients with Relapsed, Refractory, Metastatic Solid Tumors


Jun 2, 2021

Samsung Biologics and KAHR Medical Announce Development and Manufacturing Agreement for Cancer Immunotherapy Drug Candidate


Jun 2, 2021

Genmab and Bolt Biotherapeutics Announce Oncology Research and Development Collaboration


Jun 1, 2021

Istari Oncology to Present Data from its PVSRIPO Immunotherapy Platform at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting



Jun 1, 2021

Oncocyte Selected as New “Day One” Launch Site for QIAGEN’s Companion Diagnostics Test to Identify Patients for Amgen’s Newly FDA-Approved Drug LUMAKRAS (Sotorasib) For Advanced Stage Lung Cancer


May 30, 2021

Hummingbird Bioscience Announces Publication of Abstract on Anti-VISTA Antibody HMBD-002 at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting


May 27, 2021

eFFECTOR Therapeutics and Locust Walk Acquisition Corp. Announce Merger Agreement to Create Publicly Listed, Next-Generation Oncology Company Developing New Class of Cancer Therapies


May 27, 2021

enGene Announces First-in-Human Dosing of EG-70 for the Treatment of Non-Muscle Invasive Bladder Cancer in Phase 1/2 Clinical Trial


May 27, 2021

Sapience Therapeutics Enters Into Collaboration with National Cancer Institute (NCI) to Study ST101 Response in Specialized Tumor Models



May 26, 2021

Rafael Pharmaceuticals to Present New Pancreatic Cancer and Biliary Tract Cancer Data featuring CPI-613 (Devimistat) at the American Society of Clinical Oncology (ASCO) 2021 Virtual Scientific Program


May 26, 2021

KAHR Receives Investment from Cancer Focus Fund to Support Phase 1/2 Study of KAHR's Lead Anti-CD47 Candidate in Blood Cancers USA - English USA - English


May 26, 2021

KAHR Receives Investment from Cancer Focus Fund to Support Phase 1/2 Study of KAHR's Lead Anti-CD47 Candidate in Blood Cancers


May 26, 2021

CancerVAX Announces Research Program to Develop Its First Immunotherapy Cancer Treatment


May 25, 2021

Alloy Therapeutics and Pyxis Oncology Form Kyma Therapeutics to Develop Novel Immune-Modulating Antibodies for Cancer and Autoimmune Diseases



May 25, 2021

Clarus Therapeutics And HavaH Therapeutics Announce Licensing Agreement For Product To Treat Androgen-Dependent Inflammatory Breast Disease And Certain Forms Of Breast Cancer


May 20, 2021

Intensity Therapeutics Announces Two Abstracts to Be Presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting


May 20, 2021

NeoImmuneTech to Present Two Posters at American Society of Clinical Oncology Annual Meeting


May 20, 2021

BioTheryX Announces $92M Series E Financing to Accelerate Development of Targeted Protein Degradation Pipeline and Technology Platform in Oncology


May 20, 2021

Istari Oncology Honored as “Best Early Stage Product Development Company” in the Triangle Business Journal’s Life Sciences Awards



May 20, 2021

Phosplatin Therapeutics Reports Phase 1b Study Results of Immunogenic Cell Death Inducer PT-112 Plus PD-L1 Inhibitor avelumab in Metastatic Prostate Cancer at ASCO Annual Meeting


May 20, 2021

IN8bio Presents First Cohort Phase 1 Clinical Data on INB-200 at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting


May 20, 2021

Novo Holdings co-leads oversubscribed CHF 100 Million (USD 110 M) Series C in Numab Therapeutics


May 19, 2021

Apexigen Announces Presentation of Phase 2 Clinical Data on CD40 Antibody, Sotigalimab (APX005M), in Combination Therapy for Metastatic Pancreatic Cancer at the ASCO 2021 Annual Meeting


May 19, 2021

Bicara Therapeutics to Present Clinical Data from Lead Immunotherapy Program, BCA101, at the American Society of Clinical Oncology 2021 Annual Meeting



May 19, 2021

Propella Therapeutics Receives FDA Clearance to Begin Phase 1 Clinical Study of Novel Prostate Cancer Treatment


May 18, 2021

Elevation Oncology Appoints Michael Carruthers to Board of Directors and Chair of the Audit Committee


May 18, 2021

Novo Holdings leads US$125 Million Series C in Hummingbird Bioscience


May 18, 2021

Elevar Therapeutics Announce New Data Highlighting Patient Burden and Unmet Needs Associated with Cremophor-Based Cancer Treatments


May 17, 2021

Genenta Appoints Four Renowned Oncology Experts to Scientific Advisory Board



May 17, 2021

Boundless Bio Announces Educational Session on Extrachromosomal DNA (ecDNA) at the American Association for Cancer Research (AACR) Annual Meeting 2021


May 17, 2021

Sermonix Pharmaceuticals Announces Breast Cancer Research Publication of Preclinical Lasofoxifene Study in Endocrine-Resistant Breast Cancer


May 17, 2021

AffyImmune Therapeutics' AIC100 Granted Fast Track Designation for Treating Thyroid Cancer


May 13, 2021

Adagene Presents Preclinical Data from Lead SAFEbody™ Program, ADG126, at the American Association for Cancer Research (AACR) Annual Meeting 2021


May 13, 2021

LIPAC Oncology Names Daniel K. Spiegelman as Independent Board Advisor



May 13, 2021

Flare Therapeutics Launches with $82 Million Series A Financing to Advance Precision Oncology Pipeline based on Novel Drug Discovery Approach for Transcription Factors


May 13, 2021

Interline Therapeutics Launches With $92 Million to Map and Correct Dysfunctional Protein Communities


May 13, 2021

Systems Oncology to Participate in Fireside Chat at RBC Capital Markets Global Healthcare Conference


May 13, 2021

Improving Cancer Survival Prediction: A New Approach with EpiVax Therapeutics' Ancer Platform USA - English Deutschland - Deutsch España - español France - Français


May 12, 2021

Xilio Therapeutics Presents Preclinical Tumor-Selective Activity and Tolerability Data for XTX101 at Frontiers in Cancer Immunotherapy Virtual Symposium



May 12, 2021

Qu Biologics Files Important New IP for the Treatment of Post-Surgical Immune Dysfunction and Prevention of Cancer Metastasis


May 11, 2021

FDA Grants Bold Therapeutics' BOLD-100 an Orphan Drug Designation (ODD) in the Treatment of Gastric Cancer


May 6, 2021

Penrose TherapeuTx Expands Scientific Advisory Board with Three World-Renowned Oncology Researchers


May 6, 2021

Istari Oncology Abstracts to be Presented at the American Association for Cancer Research (AACR) 2021 Annual Meeting Reflect Continued Progress in the Clinical Development of PVSRIPO


May 6, 2021

Volastra Therapeutics Extends Seed Financing to $44 Million to Advance Drug Discovery Programs to Prevent Cancer Metastasis



May 6, 2021

Volastra Therapeutics Partners with Microsoft to Advance Metastatic Cancer Research


May 6, 2021

LIPAC Oncology Announces Appointment of Josh Hamermesh to the Board of Directors


May 6, 2021

ITM Establishes Subsidiary in Shanghai to Accelerate Introduction of Its Precision Oncology Portfolio in China


May 5, 2021

SEngine Precision Medicine’s PARIS Test Identifies Novel Therapeutic Options for Ovarian Clear Cell Carcinoma in Study Published in AACR’s Molecular Cancer Therapeutics


May 5, 2021

BridGene Biosciences Announces $12 Million Series A Financing to Advance the Company's Proprietary Chemoproteomic Platform and Pipeline of Oncology Programs



May 4, 2021

Exelixis Expands its Biotherapeutics Portfolio with Acquisition of GamaMabs Pharma’s First-in-Class Humanized Antibody Program Against a Novel Oncology Target


May 4, 2021

Codagenix Appoints Johanna Kaufmann, Ph.D., Executive Vice President, Oncology to Lead Customization of Oncolytic Viruses for Solid Tumors


May 3, 2021

Synthekine Appoints Internationally Recognized Cancer Immunotherapy Leader Naiyer Rizvi, M.D., as Chief Medical Officer


May 3, 2021

Lantern Pharma and Actuate Therapeutics Announce Research and Development Collaboration Leveraging Lantern's Artificial Intelligence Platform


Apr 30, 2021

Immunicom Presents Promising Preliminary Data from Multiple Studies in Late-Stage Cancer Patients at ISFA / E-ISFA Conference



Apr 29, 2021

SEngine Precision Medicine to Present Pan Cancer Data on Predictive Value of PARIS Test at 2021 ASCO Annual Meeting


Apr 29, 2021

Istari Oncology Hires Marc Banjak as General Counsel and Secretary as the Company Prepares for a Critical Period of Development and Expansion


Apr 29, 2021

LIPAC Oncology Announces Successful Type B Meeting with the U.S. FDA for the Study of LiPax for Non-Muscle Invasive Bladder Cancer


Apr 29, 2021

Candel Therapeutics’ CAN-3110 Clinical Data Selected for Oral Presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting


Apr 29, 2021

Elucida Oncology Announces Three Key Additions to Its Board of Directors and the Appointment of Robert Essner as Chairman of the Board



Apr 29, 2021

Elucida Oncology to Present Preclinical Data on ELU001 at the American Association for Cancer Research Annual Meeting


Apr 29, 2021

Adcendo raises EUR 51 Million in Series A Financing to Advance Novel Antibody-Drug Conjugates for Treatment of Cancers


Apr 29, 2021

Novo Seeds co-leads Adcendo's EUR 51 Million Series A Financing to Advance Novel Antibody-Drug Conjugates for Treatment of Cancers


Apr 28, 2021

Boundless Bio Raises Oversubscribed $105 Million Series B Financing to Advance Next-Generation Precision Oncology Therapies Directed Against Extrachromosomal DNA (ecDNA)


Apr 28, 2021

Lutris Pharma Phase 1 Results of LUT014 for Skin Toxicities Associated with Treatment of Colorectal Cancer Patients with EGFR Inhibitors Published in Cancer Discovery USA - English USA - English



Apr 28, 2021

Lutris Pharma Phase 1 Results of LUT014 for Skin Toxicities Associated with Treatment of Colorectal Cancer Patients with EGFR Inhibitors Published in Cancer Discovery


Apr 27, 2021

Pyxis Oncology Presents Preclinical Data and Details on Antibody-Drug Conjugate Candidates Supporting Therapeutic Potential


Apr 27, 2021

Shasqi Awarded Prestigious Direct-to-Phase-2 Small Business Innovation Research Grant by National Cancer Institute


Apr 26, 2021

Biond Biologics Announces First Patient Dosed in Phase 1 Clinical Trial of BND-22, a Novel Immune Checkpoint Inhibitor Targeting the ILT2 Receptor USA - English USA - English


Apr 26, 2021

Biond Biologics Announces First Patient Dosed in Phase 1 Clinical Trial of BND-22, a Novel Immune Checkpoint Inhibitor Targeting the ILT2 Receptor



Apr 25, 2021

Sirnaomics Initiates Phase 2b Study Using STP705 for Treatment of Squamous Cell Skin Cancer


Apr 22, 2021

ITM Raises EUR 90 M (USD 109 M) to Accelerate Precision Oncology Pipeline and Support Ongoing Phase 3 Clinical Program


Apr 22, 2021

Illumina and Kartos Therapeutics Announce New Oncology Partnership to Develop an NGS-Based TP53 Companion Diagnostic


Apr 21, 2021

Istari Oncology Announces Publication of Phase 1 Data Showing PVSRIPO Immunotherapy Leads to Objective Responses in Patients with Treatment-Refractory Melanoma


Apr 21, 2021

BioCurity Pharmaceuticals Inc. Files a US Provisional Patent Application Drawn to Pharmaceutical Formulations of Cerium Oxide Nanoparticles Designed to Prevent Radiation Therapy Side Effects for Cancer Patients Undergoing Radiation Therapy



Apr 21, 2021

Sermonix Pharmaceuticals Project With Huntsman Cancer Institute Researcher to Investigate Potential Effects of Lasofoxifene on ESR1 Mutations in Endometrial Cancer


Apr 20, 2021

IconOVir Bio Announces Formation of Scientific Advisory Board


Apr 20, 2021

Immunomic Therapeutics Announces License Agreement With Lineage Cell Therapeutics for Cancer Immunotherapy


Apr 20, 2021

Lineage Announces Worldwide License Agreement With Immunomic Therapeutics for an Allogeneic Cell-Based Cancer Immunotherapy Based on Its VAC Platform


Apr 19, 2021

Istari Oncology Announces FDA Clearance of IND to Initiate LUMINOS-103: A Basket Trial Evaluating the Safety and Efficacy for PVSRIPO in Patients with Advanced Solid Tumors



Apr 19, 2021

Pyxis Oncology Hosting Key Opinion Webinar on Antibody-Drug Conjugates


Apr 18, 2021

Transcenta Announced Successful First Patient Dosed in Phase I Clinical Study of TST001 Combined with CAPOX for the Treatment of Patients with First-line Locally Advanced Unresectable or Metastatic Gastric Cancer


Apr 16, 2021

AnPac Bio Reports Record Q1 for Paid CDA-Based Cancer Testing Volume in 2021, Increasing Approximately 130% Compared to Q1, 2020


Apr 15, 2021

Alchemab to Collaborate With AstraZeneca to Use Alchemab’s Drug Discovery Platform for Prostate Cancer Study


Apr 14, 2021

Tango Therapeutics and BCTG Acquisition Corp. Announce Merger Agreement to Create Publicly Listed Precision Medicine Company Focused on the Next Generation of Targeted Cancer Therapies



Apr 14, 2021

Aura Biosciences Announces Publication of Data in Cancer Immunology Research, Supporting the Immune Mediated Mechanism of Action of the Virus-Like Drug Conjugate (VDC) Technology Platform with Broad Application in Cancer Treatment


Apr 14, 2021

BERG Announces Oncology Pipeline Advancements And Biomarker Developments For Clinical Decision Support In Breast Cancer At AACR


Apr 14, 2021

StemSynergy Therapeutics’ Notch1-Selective Small Molecule Inhibitor Prevents Tumor Growth by Ablation of Cancer Stem Cells


Apr 14, 2021

Cyclica Teams Up with Top-Tier Academic Institutions to Identify a Repurposed COVID Drug


Apr 13, 2021

Actimed Therapeutics and Faraday Pharmaceuticals Announce License Agreement for S-oxprenolol



Apr 13, 2021

SEngine Precision Medicine Presents Data at 2021 AACR Annual Meeting Demonstrating Clinical Utility and Predictive Value of PARIS Test in Ovarian Cancer


Apr 13, 2021

Iterion Therapeutics Confirms Safety of Tegavivint Following Completion of Enrollment in Phase 1/2a Expansion Study in Patients with Desmoid Tumors


Apr 12, 2021

Instil Bio Presents Clinical Data in Metastatic Melanoma in a Late-Breaking e-Poster at the 2021 American Association for Cancer Research (AACR) Annual Meeting


Apr 12, 2021

Seneca Therapeutics Reports Late Breaking Information on SVV-001 from the American Association for Cancer Research’s 2021 Annual Meeting


Apr 12, 2021

Amunix Presents Preclinical Data at American Academy of Cancer Research (AACR) Annual Meeting from Lead Program AMX-818 Demonstrating Robust Efficacy in HER2 Tumor Models and Enhanced Safety



Apr 10, 2021

Elevation Oncology Announces the Presentation of New Preclinical Data in Pancreatic and Cholangiocarcinoma PDX Models on the Specific Inhibition of HER3 with Seribantumab to Block NRG1 Fusion Signaling


Apr 10, 2021

Tallac Therapeutics Presents New Data on Toll-like Receptor Agonist Antibody Conjugate, TAC-001, at the 2021 Virtual Annual Meeting of the American Association for Cancer Research (AACR)


Apr 10, 2021

Boundless Bio Presents Data on the Role of Extrachromosomal DNA (ecDNA) in Mediating Resistance to Targeted Therapies at the American Association for Cancer Research (AACR) Annual Meeting 2021


Apr 9, 2021

CARISMA Therapeutics to Present Data at The American Association for Cancer Research Annual Meeting


Apr 9, 2021

MiNA Therapeutics Presents Translational Data at AACR Supporting MTL-CEBPA as Immunological Cancer Combination Treatment



Apr 9, 2021

Celularity Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021


Apr 9, 2021

Systems Oncology to Present at BMO BioPharma Spotlight Series


Apr 8, 2021

Volastra Therapeutics Co-founder Samuel Bakhoum to Deliver Plenary Presentation at American Association for Cancer Research Annual Meeting 2021


Apr 8, 2021

DSS Expands its Healthcare Segment through Investment in Vivacitas Oncology


Apr 8, 2021

Context Therapeutics and Integral Molecular Enter Collaboration and License Deal for Novel Claudin 6 Antibodies for Gynecologic Cancer Therapeutic Program



Apr 7, 2021

Artios Pharma Announces Collaboration with Novartis to Create Next Generation DDR Cancer Therapies


Apr 6, 2021

Elevation Oncology Announces Clinical Cancer Research Publication Highlighting the Specific Inhibition of HER3 by Seribantumab in Preclinical NRG1 Fusion Models


Apr 6, 2021

MitoImmune Received FDA Clearance of IND Application for MIT-001, a Novel Anti-Inflammatory/Anti-Necrotic Therapy for Oral Mucositis in CCRT patients with Head and Neck Cancer


Apr 6, 2021

Hadassah and MyBiotics to Collaborate for the Discovery of Microbiome-Based Therapy for Improving Cancer Immunotherapy USA - English USA - English


Apr 6, 2021

Sapience Therapeutics Announces Multiple Posters, Including Late-Breaker, at the American Association for Cancer Research (AACR) Annual Meeting 2021



Apr 5, 2021

Teon Therapeutics to Present Preclinical Proof of Concept Data at American Association for Cancer Research (AACR) Conference


Apr 1, 2021

KAHR Announces Exclusive Licensing Agreement with Thomas Jefferson University for Novel Platform of Bi- and Tri-Specific Fusion Proteins for Cancer Immunotherapy USA - English USA - English


Apr 1, 2021

KAHR Announces Exclusive Licensing Agreement with Thomas Jefferson University for Novel Platform of Bi- and Tri-Specific Fusion Proteins for Cancer Immunotherapy


Mar 31, 2021

Istari Oncology Announces First Patient Dosed in the LUMINOS-102 Phase 2 Clinical Trial of PVSRIPO With and Without Immune Checkpoint Blockade in Advanced PD-1/L1 Refractory Melanoma


Mar 31, 2021

Boundless Bio Announces Upcoming Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2021



Mar 31, 2021

OnQuality Pharmaceuticals Announces Closing of $35 Million Series A+ Financing


Mar 31, 2021

Myeloid Therapeutics Appoints Elaine Jones, Ph.D., to its Board of Directors


Mar 31, 2021

Edison Oncology Partners DNA-damage Response Inhibitor Program with Rakovina Therapeutics


Mar 30, 2021

Pyxis Oncology Closes $152 Million Series B Financing to Further Advance Portfolio of Biologics


Mar 30, 2021

Applied BioMath, LLC Announces Collaboration with Asher Biotherapeutics for Systems Pharmacology Modeling in Oncology



Mar 29, 2021

Cytocom to Present at the Spring 2021 Virtual Oncology Investor Conference


Mar 29, 2021

CORRECTING and REPLACING Fortis Therapeutics Closes $40 Million Series A Financing to Advance Novel Anti-CD46 Therapeutic to Treat Late-Stage Prostate Cancer and Multiple Myeloma


Mar 26, 2021

Oncology Investors to Hear “Cancer Device Company of the Year” Immunicom Present at MedInvest Conference


Mar 25, 2021

Istari Oncology Announces Publication of Data Showing the Investigational Immunotherapy PVSRIPO Leads to Robust, Functional T Cells—Critical for Antitumor Immunity


Mar 24, 2021

Intensity Therapeutics, The Ottawa Hospital and The Ontario Institute for Cancer Research Sign Agreements to Conduct a Phase 2 Randomized, Window of Opportunity Trial in Early-Stage Breast Cancer



Mar 23, 2021

Selexis and Tallac Therapeutics Collaborate to Advance Tallac’s Pipeline of Novel Immunotherapies in Oncology


Mar 23, 2021

GigaGen to Present Poster at the 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting


Mar 23, 2021

Asher Bio Launches with $55 Million Series A Financing Led by Third Rock Ventures to Discover and Develop Highly Specific Immunotherapies Using a Novel Technology Platform


Mar 22, 2021

Aura Biosciences Announces Oversubscribed $80 Million Financing


Mar 22, 2021

LDC and Cumulus Oncology announce collaboration



Mar 19, 2021

Cygnal Therapeutics to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2021


Mar 18, 2021

Pyxis Oncology Announces Worldwide Licensing Agreement with Pfizer to Develop and Commercialize Multiple Antibody-Drug Conjugates


Mar 18, 2021

Boston Pharmaceuticals Enters into Unique Multi-Year Out-License and Option Agreement with GSK for the Advancement of Multiple Pre-Phase 2 Programs


Mar 18, 2021

Aktis Oncology Announces $72M Series A Financing To Advance Breakthrough Radiopharmaceuticals To Treat Solid Tumors


Mar 17, 2021

Ambrx Granted Orphan Drug Designation for ARX788 for the Treatment of Gastric Cancer



Mar 16, 2021

Elevation Oncology and NeoGenomics Announce Collaboration to Expand Genomic Testing for NRG1 Fusions Across Solid Tumors in Support of the Phase 2 CRESTONE Study


Mar 15, 2021

ALX Oncology Announces Appointment of Sophia Randolph, M.D., Ph.D., to Board of Directors


Mar 15, 2021

VLP Therapeutics raises $16M Series A for cancer treatment vaccine RandD


Mar 15, 2021

Bicara Therapeutics Launches with Deep Pipeline of First-in-Class Dual Action Biologics for Cancer Immunotherapy


Mar 15, 2021

Seneca Therapeutics Announces Acceptance of Late Breaking SVV-001 Abstract to American Association for Cancer Research Annual Meeting April 10-15, 2021



Mar 11, 2021

ImCheck to Present Data Demonstrating Activation of the Anti-Tumor Immune Response of Gamma9 Delta2 T Cells in Cancer Patients from the Ongoing Phase I/IIa EVICTION Trial at the AACR Annual Meeting 2021


Mar 11, 2021

Nouscom receives approval to begin Phase 1b trials of NOUS-PEV, a novel personalized cancer immunotherapy


Mar 10, 2021

LAVA Therapeutics B.V. to Present Preclinical Findings Supporting Anti-Tumor Activity of Lead Clinical Candidate LAVA-051 at the American Association for Cancer Research (AACR) Virtual 2021 Annual Meeting


Mar 10, 2021

Enveric Biosciences Signs Definitive Agreement to Acquire Exclusive License for Novel Molecules from Diverse Biotech


Mar 10, 2021

PMV Pharmaceuticals Announces Presentation of PC14586 Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2021



Mar 10, 2021

Prominent Mitochondrial Researcher Dr. Navdeep Chandel Joins Penrose TherapeuTx Scientific Advisory Board


Mar 10, 2021

SEngine Precision Medicine to Present Data on Predictive Value of PARIS Test in Ovarian Cancer Patients at 2021 AACR Annual Conference


Mar 9, 2021

MD Anderson’s Therapeutics Discovery Division, Orionis Biosciences Launch Project Helios to Advance Novel Small-Molecule Cancer Medicines


Mar 9, 2021

Volastra Therapeutics and Dewpoint Therapeutics Partner to Discover Novel Condensate Modulators for Cancer Treatment


Mar 8, 2021

Wugen Announces Exclusive Partnership Agreement With Alpha Biopharma in Asia For Cell Therapies to Treat Cancer



Mar 4, 2021

DNAtrix Announces First Patient Dosed in Clinical Study of DNX-2440, an OX40 Ligand Expressing Immunotherapy, in Colorectal Cancer and Other Cancers with Liver Metastasis


Mar 4, 2021

ALX Oncology and Tallac Therapeutics Announce Collaboration on Novel Class of Cancer Immunotherapeutics


Mar 4, 2021

Amunix Raises $117 Million Series B Financing to Fund its Oncology Pipeline


Mar 3, 2021

Janux Therapeutics Announces $56 Million Series A to Advance Novel Cancer Drug Candidates Using T Cell Engager (TRACTr) Technology


Mar 3, 2021

Geneos Therapeutics Secures $12 Million in Series A1 Financing to Advance Personalized Cancer Immunotherapy Programs



Mar 2, 2021

Wugen Announces Exclusive License Agreement With HCW Biologics For Cell Therapies to Treat Cancer


Mar 2, 2021

ALX Oncology to Participate at H.C. Wainwright Global Life Sciences Conference


Mar 2, 2021

Orbus Therapeutics Announces Positive Outcome of Pre-Planned Interim Futility Analysis for Phase 3 Eflornithine STELLAR Study


Mar 1, 2021

CytoImmune Therapeutics Establishes Operations in Puerto Rico to Develop Novel Cancer Immunotherapy Products


Feb 24, 2021

Cybrexa Therapeutics Enters Cooperative Research and Development Agreement (CRADA) with U.S. National Cancer Institute to Develop CBX-12 (alphalex™- exatecan)



Feb 22, 2021

NovellusDx Establishes Fore Biotherapeutics U.S. as its Operating Company in the United States and Appoints Dieter Weinand as Chairman of the Board and Usama Malik as Chief Executive Officer and Director of the Board


Feb 17, 2021

Edison Oncology to Participate in the 10th Annual SVB Leerink Global Healthcare Conference


Feb 16, 2021

ImmunityBio Announces ASCO Genitourinary Cancer Symposium Presentation of Phase 2/3 Trial for BCG Unresponsive Non-Muscle Invasive Bladder Cancer CIS with 71% Complete Response Rate


Feb 16, 2021

Iterion Therapeutics Secures $17 Million to Advance Development of Tegavivint in Multiple Tumor Settings


Feb 11, 2021

DNAtrix Announces Preclinical Data Demonstrating Anti-Tumor Activity of DNX-2401 in Models of Pediatric Tumors (AT/RT and CNS-PNET) Published in Clinical Cancer Research



Feb 11, 2021

Penrose TherapeuTx Appoints Oncology Clinical Development Veteran Bhardwaj Desai, M.D. as Chief Development Officer


Feb 10, 2021

Nuvation Bio Closes Transaction with Panacea, Debuts as Publicly Traded Oncology Company


Feb 10, 2021

Shasqi Announces Strategic Advisors as it Advances Click-Chemistry Based Treatments for Cancer


Feb 10, 2021

Notch Therapeutics Closes $85 Million Series A Financing to Develop Pipeline of Renewable Stem Cell-Derived Cancer Immunotherapies


Feb 9, 2021

Cambrian Biopharma announces $60M in financing to develop a pipeline of companies and therapeutics to treat diseases of aging, coupled with a unique operational strategy



Feb 5, 2021

Global Atypical Teratoid Rhabdoid Tumors (ATRT) Pipeline Insights Report 2020 Featuring Takeda Oncology, Epizyme, Vyriad, Novartis, DNAtrix, Pfizer, Oncoceutics and Istari Oncology - ResearchAndMarkets.com


Feb 2, 2021

MAIA Biotechnology, Inc. Announces Clinical Supply Agreement with Regeneron for Phase 1/2 Clinical Trial Evaluating THIO in Sequential Administration with Libtayo (cemiplimab) in Advanced Non-Small Cell Lung Cancer


Feb 1, 2021

Advanced Pancreatic Cancer Pipeline Therapeutics and Analysis, 2021


Jan 28, 2021

ImmunityBio Announces Positive Phase 2 Results Showing That Anktiva Restores the Activity of Checkpoint Inhibitors in Patients Who Have Relapsed Checkpoint Immunotherapy in Non-Small Cell Lung Cancer


Jan 26, 2021

OS Therapies Receives Trial Approval From Children's Oncology Group for AOST2121 / OST31-164-01 An Open-Label Phase 2 Study of Maintenance Therapy With OST31-164 After Resection of Recurrent Osteosarcoma



Jan 25, 2021

Immunicom Makes StartUpCity’s Global “Ten Most Promising 2020 Biotech Startups”


Jan 21, 2021

CureLab Oncology Launches Veterinary Oncology Subsidiary, CureLab Veterinary


Jan 21, 2021

Curelab Veterinary Launches in Animal Health Sector, Leveraging Technology Licensed from CureLab Oncology


Jan 19, 2021

Compass Therapeutics to Participate in the B. Riley Securities Virtual Oncology Investor Conference


Jan 19, 2021

Second Genome To Present Biomarker Data in Oncology at Keystone Symposium



Jan 19, 2021

Rafael Pharmaceuticals to Present at B. Riley Securities Virtual Oncology Investor Conference


Jan 18, 2021

Propanc Biopharma Receives Expression of Interest to Evaluate Proenzyme Therapy in Pancreatic and Ovarian Cancer Patients


Jan 14, 2021

Adastra Pharmaceuticals, Inc. to Present at Inaugural B. Riley Securities' Oncology Investor Conference


Jan 13, 2021

IO Biotech Completes Oversubscribed EUR 127 Million Series B Financing to Accelerate Clinical Programs in Oncology


Jan 13, 2021

Novo Seeds' Portfolio Company, IO Biotech, Completes Oversubscribed EUR 127M Series B Financing to Accelerate Clinical Programs in Oncology



Jan 13, 2021

Adastra Pharmaceuticals Announces Positive Top-Line Data from Phase 1b Clinical Trial of Zotiraciclib in the Treatment of Recurrent High-grade Gliomas


Jan 13, 2021

NantKwest, ImmunityBio Announce Positive Interim Data on Survival Rates in Metastatic Pancreatic Cancer Trials


Jan 13, 2021

HiberCell and Biodesix Initiate Broad Collaboration for Companion Diagnostic Discovery, Development and Commercialization


Jan 13, 2021

Cytovia Therapeutics Partners with National Cancer Institute to Develop Novel Gene-Edited, iPSC-Derived GPC3 CAR NK Cells for the Treatment of Solid Tumors


Jan 12, 2021

Elucida Oncology Closes $44 Million Series A-1 Financing



Jan 12, 2021

Global $3.9 Bn Microbiome Therapeutics Markets to 2030: Market Opportunities with the Growing Eminence of Microbiome Therapeutics in Cancer Treatment


Jan 12, 2021

DIACCURATE acquires BIOKINESIS to create a sole-in-class biotech player in oncology and immunotherapy


Jan 11, 2021

Sensei Biotherapeutics Announces $30 Million Financing to Advance Clinical Pipeline of Oncology Therapeutics and Proprietary ImmunoPhage™ Platform


Jan 11, 2021

Istari Oncology Announces FDA Grants Orphan Drug Designation for PVSRIPO for the Treatment of Advanced Melanoma


Jan 11, 2021

Rakuten Medical, Inc. Acquires Key Assets and Manufacturing Technology from LI-COR Biosciences



Jan 11, 2021

EXUMA Biotech Announces Collaboration with Moffitt Cancer Center for the Development of a Rapid-Point-Of-Care SC CAR-T Program


Jan 8, 2021

Chimerix Acquires Oncoceutics to Expand Pipeline with Late-Stage Oncology Program


Jan 8, 2021

Cellares Adds PACT Pharma to its Early Access Partnership Program USA - English España - español Deutschland - Deutsch France - Français


Jan 8, 2021

ATP and Biolojic Design Launch Aulos Bioscience to Develop Highly Differentiated IL-2 Antibody Approach to Fighting Cancer USA - English USA - English USA - English España - español España - español Deutschland - Deutsch Deutschland - Deutsch France - Français France - Français


Jan 8, 2021

ATP and Biolojic Design Launch Aulos Bioscience to Develop Highly Differentiated IL-2 Antibody Approach to Fighting Cancer USA - English Israel - English USA - español USA - Deutsch USA - Français



Jan 8, 2021

ATP et Biolojic Design lancent Aulos Bioscience pour développer une approche hautement différenciée des anticorps IL-2 dans la lutte contre le cancer USA - Français USA - English Israel - English USA - español USA - Deutsch


Jan 7, 2021

Werewolf Therapeutics Completes $72 Million Series B Financing to Advance a Novel Class of Cancer Biotherapeutics to the Clinic


Jan 7, 2021

Elucida Oncology to Present at the 39th Annual J.P. Morgan Healthcare Conference


Jan 7, 2021

BlueRock Therapeutics in Collaboration with Memorial Sloan Kettering Cancer Center Receives IND Clearance for DA01 in Parkinson's Disease


Jan 7, 2021

Scorpion Therapeutics Announces Oversubscribed $162 Million Series B Financing



Jan 7, 2021

ArsenalBio Announces Multi-Program Discovery Collaboration with Bristol Myers Squibb to Advance Next-Generation T cell Therapies for Solid Tumors


Jan 6, 2021

Myeloid Therapeutics Launches with Over $50 Million in Financing and Two Clinical Trials


Jan 6, 2021

Elevation Oncology to Present at the 39th Annual J.P. Morgan Healthcare Conference


Dec 30, 2020

ImmunityBio Appoints Fabio M. Benedetti, M.D., as Chief Strategy Officer


Dec 23, 2020

Rakuten Medical Enrolls First Patient in the U.S. Clinical Trial for its Lead Product, ASP-1929 in Combination with Anti-PD1 Therapy, for Head and Neck Cancer or Cutaneous Squamous Cell Carcinoma



Dec 21, 2020

Servier and Celsius Therapeutics Announce Target Discovery Collaboration in Colorectal Cancer


Dec 21, 2020

ImmunityBio Announces Primary Endpoint Met of Phase 2/3 Trial for BCG Unresponsive Non-Muscle Invasive Bladder Cancer CIS with 72% Complete Response Rate


Dec 20, 2020

Sirnaomics Reports Positive Data from Phase 2a Study of STP705 for Treatment of Squamous Cell Skin Cancer


Dec 17, 2020

Cullinan Oncology Completes $131.2 Million Series C Financing


Dec 14, 2020

Teon Therapeutics Announces Approval for Collaboration with Cancer Research UK



Dec 14, 2020

ALX Oncology Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares


Dec 10, 2020

Ambrx Presents Phase 1 Trial Data Update and Phase 2/3 Clinical Trial in Progress for Lead Program ARX788 at the 2020 San Antonio Breast Cancer Symposium


Dec 10, 2020

Denovo Biopharma Acquires a Novel Late-Stage Oncology Drug and Expands into Protein Therapeutics


Dec 10, 2020

Silicon Therapeutics Announces Members of Scientific Advisory Board


Dec 10, 2020

LIPAC Oncology Announces Major Partnering Milestone Achieved in its License Agreement with Huons Co., Ltd.



Dec 10, 2020

Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates


Dec 10, 2020

CG Oncology Closes $47 Million Series D Financing


Dec 9, 2020

North America Cancer Vaccines Market Report 2020-2027 Featuring Leading Players - AstraZeneca, GSK, Aduro Biotech, Pfizer, Sanofi, Bristol-Myers Squibb, Moderna, OncBioMune, MaxiVAX, Nouscom


Dec 9, 2020

Bolt Biotherapeutics Presents Ongoing Clinical Trial Poster at San Antonio Breast Cancer Symposium 2020 Virtual Meeting


Dec 9, 2020

ALX Oncology Announces Pricing of Upsized Public Offering of Common Stock



Dec 9, 2020

SEngine Precision Medicine Presents Data Summarizing Predictive Value of PARIS Test in Breast Cancer Patients at 2020 San Antonio Breast Cancer Symposium


Dec 9, 2020

CG Oncology Announces First Patient Dosed in Phase 2 Clinical Trial of CG0070, an Oncolytic Immunotherapy, in Combination with KEYTRUDA (pembrolizumab) for Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin


Dec 9, 2020

Immutep’s Chinese Partner EOC Pharma to Start Phase II Metastatic Breast Cancer Study


Dec 9, 2020

Boehringer Ingelheim to Acquire Labor Dr. Merk and Kollegen to Strengthen its Next Generation Cancer Immunology Program


Dec 8, 2020

RayzeBio Completes $105M Series B Financing to Advance Targeted Radiopharmaceuticals for Cancer



Dec 8, 2020

Candel Therapeutics Appoints Pharma Veteran and Immunologist Paul-Peter Tak, M.D., Ph.D., as Chief Executive Officer; Expands Leadership Team With Chief Financial Officer, Chief Business Officer and Chief Regulatory Officer Appointments


Dec 7, 2020

Data Published in Nature Cancer Highlight Preclinical Proof of Concept of Bolt Biotherapeutics' Boltbody™ ISAC Platform


Dec 7, 2020

ALX Oncology Announces Proposed Public Offering of Common Stock


Dec 7, 2020

ALX Oncology Announces Updates on Planned ALX148 Phase 2 Head and Neck Cancer Studies


Dec 7, 2020

ALX Oncology Announces Updated Data from ASPEN-01, the Ongoing Phase 1b Study of ALX148, Showing Robust, Durable Activity in Patients with Non-Hodgkin Lymphoma



Dec 7, 2020

Boehringer Ingelheim Collaborates with Proxygen to Explore Molecular Glue Degraders - a Novel Approach to Fight Cancer


Dec 3, 2020

enGene Receives Fast Track Designation for EG-70 for the Treatment of Non-Muscle Invasive Bladder Cancer


Dec 3, 2020

Merck KGaA, Darmstadt, Germany and Artios Pharma Announce a Global Strategic Collaboration on Novel DNA Damage Response Targets in Oncology


Dec 3, 2020

Sermonix to Present Poster on Phase 2 Study of Lasofoxifene in Combination with Eli Lilly and Company’s Abemaciclib at Virtual San Antonio Breast Cancer Symposium 2020


Dec 3, 2020

Sirnaomics to Initiate Phase I Study of STP705 in Treatment of Primary and Metastatic Liver Cancer



Dec 3, 2020

IN8bio announces first-in-human Phase 1 trial Update from The University of Kansas Cancer Center using INB-100, IN8bio’s Gamma Delta T-cell product candidate, at ASH 2020


Dec 3, 2020

IN8bio Presents Gamma-Delta T Cells as Cancer Therapeutics at the ESMO Targeted Anticancer Therapies Virtual Conference 2021


Dec 2, 2020

Sermonix to Present Poster on Patient Awareness of ESR1 Mutation Biomarker Testing, Attitudes on Metastatic Breast Cancer Quality of Life at Virtual San Antonio Breast Cancer Symposium 2020


Dec 2, 2020

Biosight Closes $46M Series C Financing to Advance Clinical Oncology Programs


Dec 2, 2020

Frontier Medicines and AbbVie Establish Global Partnership to Discover and Develop Novel Therapies and E3 Degraders Against Difficult-to-Drug Targets



Dec 2, 2020

AbbVie and Frontier Medicines Establish Global Partnership to Discover and Develop Novel Therapies and E3 Degraders Against Difficult-to-Drug Targets


Dec 1, 2020

Darrin M. Beaupre, M.D., Ph.D. joins Samumed as Chief Medical Officer, Oncology


Dec 1, 2020

LianBio Announces Clearance to Initiate in China the Phase 2a Trial of Infigratinib in Patients with Locally Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma with FGFR2 Gene Amplification


Dec 1, 2020

Calidi Biotherapeutics Announces European Patent Granted by EPO: Combination Immunotherapy Approach for Treatment of Cancer


Dec 1, 2020

Tallac Therapeutics Launches with $62 Million in Series A Financing to Advance Novel Immunotherapies for Cancer



Nov 30, 2020

Istari Oncology Announces First Patient Dosed in the LUMINOS-101 Phase 2 Clinical Trial of PVSRIPO in Combination with Pembrolizumab for Patients with Recurrent Glioblastoma


Nov 24, 2020

Integral Molecular Announces Best-in-Class Antibodies Against Complex Oncology Target Claudin 18.2


Nov 24, 2020

SEngine Precision Medicine to Present Data from Predictive Value of PARIS Test in Breast Cancer Patients at 2020 San Antonio Breast Cancer Symposium


Nov 23, 2020

ImmunityBio Announces Publication of Preclinical Data Demonstrating IL-15 Superagonist N-803 Improves Natural Killer-Mediated Tumor Cell Killing


Nov 23, 2020

PMV Pharma Doses First Patient in Phase 1/2 Study of PC14586, a First-in-Class Precision Oncology Therapy That Targets Mutant p53



Nov 23, 2020

Penrose TherapeuTx Appoints Business Leader Mark de Souza as Chief Executive Officer to Help Drive New Innovations in Oncology


Nov 20, 2020

Antengene Corporation, an Innovative Cancer Biotech Company, is Listed on the Main Board of the Hong Kong Stock Exchange


Nov 19, 2020

Elevar Therapeutics Presents Safety and Efficacy Results of Rivoceranib (apatinib) in Combination with Nivolumab at the 2020 Connective Tissue Oncology Society (CTOS) Annual Meeting


Nov 18, 2020

Elevation Oncology Announces $65M Series B Financing and Promotion of Founder Shawn M. Leland to Chief Executive Officer


Nov 18, 2020

AUM Biosciences and Newsoara Biopharma Announce a 5-year Transformational Strategic Partnership to Co-develop and Co-discover Next-generation Cancer Therapeutics



Nov 17, 2020

AIVITA Biomedical's Phase 2 Glioblastoma Trial Shows Improved Progression Free Survival


Nov 16, 2020

Zymeworks and ALX Oncology Announce Clinical Collaboration Evaluating Zanidatamab with the CD47 Blocker ALX148 in Patients with Advanced HER2‑Expressing Breast Cancer


Nov 16, 2020

NeoImmuneTech Receives U.S. FDA IND Clearance for Phase 2 Study of NT-I7 (efineptakin alfa) in combination with PD-L1 checkpoint inhibitor in First-line Non-small Cell Lung Cancer


Nov 16, 2020

Istari Oncology Announces FDA Clearance of New IND to Open LUMINOS-102: PVSRIPO with and without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma


Nov 12, 2020

Jubilant Therapeutics and OneThree Biotech Collaborate to Advance Precision Oncology English Français Deutsch



Nov 12, 2020

Metagenomi closes USD 65 million Series A financing led by Leaps by Bayer and Humboldt Fund


Nov 12, 2020

CG Oncology Announces First Patient Dosed in Phase 1b Study of Oncolytic Immunotherapy CG0070 in Combination with OPDIVO (nivolumab) in Muscle-Invasive Bladder Cancer


Nov 12, 2020

Jubilant Therapeutics and OneThree Biotech Collaborate to Advance Precision Oncology USA - English USA - Français USA - Deutsch


Nov 11, 2020

Vor Biopharma Announces Exclusive License of Clinical-Stage CD33 CAR-T from National Cancer Institute


Nov 10, 2020

Aura Biosciences Announces AU-011 Data From Phase 1b/2 Clinical Trial Selected for Late Breaking Presentation at the Upcoming American Academy of Ophthalmology 2020 Virtual Annual Meeting



Nov 10, 2020

Genexine and NeoImmuneTech Announce Data Release for their Phase 1b/2 Study of GX-I7/NT-I7 (efineptakin alfa) and KEYTRUDA (pembrolizumab) in patients with Triple-negative Breast Cancer


Nov 10, 2020

Bolt Biotherapeutics Presents BDC-1001 Ongoing Clinical Trial Design and Supportive Preclinical Data at Society for Immunotherapy of Cancer Annual Meeting


Nov 10, 2020

Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613 (devimistat) for the Treatment of Pancreatic Cancer


Nov 10, 2020

Xilio Therapeutics to Present Data on Tumor-Selective Immunotherapies at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting


Nov 9, 2020

Werewolf Therapeutics Appoints Dr. Randi Isaacs as Chief Medical Officer



Nov 9, 2020

Arch Oncology to Present New Preclinical Data on Highly Differentiated Anti-CD47 Antibody AO-176 at SITC 2020


Nov 9, 2020

Apexigen Announces First Preclinical Data Presentations On Novel Anti-TNFR2 And Anti-SIRPα Antibody Programs At The 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting


Nov 9, 2020

Quest Announces that OncoQuest Pharmaceuticals Inc. Doses First Patient in Phase 3 Clinical Trial, FLORA-5, of Company's Lead Investigational Drug, Oregovomab, in Frontline Ovarian Cancer and appoints Dr. Sunil Gupta as Chief Medical Officer


Nov 9, 2020

Sensei Biotherapeutics Presents Additional Data from Phase 1/2 Clinical Trial of SNS-301 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting


Nov 9, 2020

Apexigen Announces First Preclinical Data Presentations On Novel Anti-TNFR2 And Anti-SIRPalpha Antibody Programs At The 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting



Nov 9, 2020

Istari Oncology Presents Positive Data from Phase 1 Study of PVSRIPO in Patients with Unresectable Treatment Refractory Melanoma at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting


Nov 9, 2020

Cygnal Therapeutics to Present Poster at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting


Nov 5, 2020

AVEO Oncology and EUSA Pharma Announce Annals of Oncology Publication of Data from Phase 1b/2 TiNivo Study in Renal Cell Carcinoma


Nov 4, 2020

NanOlogy Enrolls First Patient in Phase 2 Clinical Trial of NanoPac for Intratumoral Treatment of Prostate Cancer


Nov 2, 2020

AIVITA Biomedical Completes Treatment of Patients in Phase 2 Clinical Trial of Glioblastoma Immunotherapy



Nov 2, 2020

enGene Announces FDA Clearance of IND Application for EG-70, an intravesical dual-immune modulator for the treatment of non-muscle invasive bladder cancer


Oct 29, 2020

Cullinan Oncology Appoints Jeff Trigilio as Chief Financial Officer


Oct 29, 2020

AffyImmune Therapeutics Announces First Patient Enrolled in Phase I Clinical Trial of AIC100 CAR T cells for the Treatment of Advanced, Refractory Thyroid Cancer USA - English USA - English


Oct 29, 2020

Worldwide Dendritic Cell Cancer Vaccine Immunotherapy Industry to 2026 - Featuring 3M, Activartis and Argos Therapeutics Among Others


Oct 29, 2020

AffyImmune Therapeutics Announces First Patient Enrolled in Phase I Clinical Trial of AIC100 CAR T cells for the Treatment of Advanced, Refractory Thyroid Cancer



Oct 27, 2020

Syntrix Completes Initial SX-682 Dosing in Broad Phase 1/2 Cancer Trial Campaign Now Encompassing 5 Solid Cancer Types Plus Myelodysplastic Syndromes


Oct 27, 2020

Prokarium Closes $21M Series B Financing Round and Strengthens Board


Oct 26, 2020

Arch Oncology to Present at Upcoming Conferences


Oct 26, 2020

Boundless Bio Presents Research Showcasing its Imaging and Single-Cell Sequencing Platform for Extrachromosomal DNA (ecDNA) Detection at the 2020 American Society of Human Genetics (ASHG) Virtual Annual Meeting


Oct 26, 2020

Elevation Oncology Announces the Presentation of Preclinical Data on the Specific Inhibition of HER3 with Seribantumab to Block NRG1 Fusion Signaling



Oct 26, 2020

Scorpion Therapeutics Launches with $108 Million to Advance Precision Oncology 2.0


Oct 22, 2020

Phosplatin Therapeutics Doses First Patient in Phase 2 Study of PT-112 in Metastatic Castration Resistant Prostate Cancer Patients


Oct 22, 2020

Orbus Therapeutics Expands Series A Financing to $71 Million to Support Ongoing STELLAR Phase 3 Study in Rare Brain Cancer


Oct 21, 2020

Nuvation Bio and Panacea Announce Business Combination Agreement, Creating a Publicly Listed Leader in Oncology Drug Development


Oct 21, 2020

NeoImmuneTech Announces a Second Clinical Collaboration with Roche to Evaluate NT-I7 (efineptakin alfa) in Combination with PD-L1 checkpoint inhibitor in First-line Non-small Cell Lung Cancer



Oct 21, 2020

CureLab Oncology Establishes Operations in the Gulf Region USA - English USA - English USA - English


Oct 21, 2020